| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Supernus Pharmaceuticals, Inc.$48.46
-0.29 (-0.59%)
B 71Pipeline Score Undervalued Pharma · Commercial
Market Cap
2.80 B
EPS
-0.51
P/E Ratio
-
Value Trade
44.11 M
SEC Financials
Q1 2026Dilution Risk
Revenue
207.71 M
R&D Expenses
39.44 M
Operating CF
66.52 M
Total Assets
1.50 B
Total Liabilities
423.92 M
Equity
1.08 B
D/E Ratio
12,345
-5.25 %
Week
-2.45 %
1 Month
-6.35 %
3 Month
7.78 %
6 Month
53.19 %
5 Year
641.69 %
All Time
Cash Data
Cash Position
384.24 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
1.13 M
52 Week Range
30.83 - 59.68
% held by Insiders
6.2 %
% held by Institutions
98.98 %
Enterprise Value
2.45 B
Total Shares
58.03 M
Short %
12.9 %
Float Shares
55.36 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Supernus Pharmaceuticals, Inc.
657Total events
6Upcoming
177Tier-1 (high impact)
2012 – 2027Coverage
Upcoming catalysts 6
Event history 651
Q3 2026
●NDA SubmissionONAPGOApprovedRegulatory Filing
Regulatory submission to FDA for second supplier for ONAPGO
Parkinson's diseasesource ↗
Jun 30, 2026
◆Milestone PaymentZURZUVAECorporate
CVR milestone: first commercial sale in Japan for MDD after regulatory approval by June 30, 2026
major depressive disordersource ↗
Jun 30, 2026
◆Other Regulator MilestoneZURZUVAEEx-US Regulatory
First commercial sale after regulatory approval in Japan for ZURZUVAE in MDD
Major Depressive Disordersource ↗
Jun 30, 2026
◆Product LaunchZURZUVAEPost-Market
First commercial sale of ZURZUVAE in Japan for MDD
Major Depressive Disordersource ↗
Jun 8, 2026
◆Oral PresentationPresentation
Supernus management to participate in Goldman Sachs 47th Annual Global Healthcare Conference
Jun 3, 2026
◆Oral PresentationPresentation
Supernus management to participate in Jefferies Global Healthcare Conference fireside chat
May 12, 2026
◆Oral PresentationPresentation
Supernus Pharmaceuticals to participate in fireside chat at Bank of America 2026 Health Care Conference
Mar 11, 2026
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
Mar 2, 2026
Feb 24, 2026
Drug Pipeline Intelligence
B71
Pipeline Score $9.2B
Pipeline ValueUndervalued
Valuation Signal27
Drugs Scored11.0x
rNPV / MCap Top 94%
Small Cap (rank 56 of 911)
Percentile RankSupernus Pharmaceuticals, Inc. holds a solid B-grade pipeline (71/100), with $14.2B risk-adjusted pipeline value, led by ADS-5102, in Multiple Sclerosis (Phase 3), across $158B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADS-5102, Small molecule | Multiple Sclerosis | Phase 3 | NCT03567057 | 64% | $4.7B | COMPLETED | 424 | - | - | Apr 18, 2021 | - | Jan 18, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SPN-820 | treatment-resistant depression | Phase 2b | 2025-02-18 | SPN-820 LS mean Standard Error -12.3 0.96 vs. placebo -11.9 0.96 p not significant Read More | Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms Read More | |
SPN-820 | treatment-resistant depression | Phase 2b | 2025-02-18 | SPN-820 LS mean Standard Error -12.3 0.96 vs. placebo -11.9 0.96 p not significant Read More | Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms Read More | |
SPN-820 | treatment-resistant depression | Phase 2b | 2025-02-18 | SPN-820 LS mean Standard Error -12.3 0.96 vs. placebo -11.9 0.96 p not significant Read More | Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SUPN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SUPN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SUPNSupernus Expands Partnership With MERGE as AI-Powered Agency of Record
Supernus Pharmaceuticals has expanded its partnership with MERGE, selecting them as the Agency of Record (AOR). This collaboration aims to enhance digital marketing strategies using AI-driven data and technology solutions, focusing on personalized communication for both existing and new products, including QELBREE for ADHD. The expanded partnership illustrates a strong, trust-based relationship developed over seven years and signifies a commitment to innovative healthcare communication experiences. MERGE will manage Supernus's digital ecosystem, supporting their portfolio in CNS diseases.
Read more →SUPNSupernus Pharmaceuticals to Participate in June Investor Conferences
Supernus Pharmaceuticals, Inc. announced its participation in several investor conferences in June. Investors can arrange meetings with management during these events. A live audio webcast of the Jefferies Global Healthcare Conference will be available on the company's website, along with archived replays for 60 days post-conference. The company focuses on CNS disease treatments.
Read more →SUPNSupernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals will participate in the Bank of America 2026 Health Care Conference on May 12, 2026. CEO Jack A. Khattar will lead a fireside chat at the event. Investors can arrange meetings with management and access a live audio webcast of the presentation. The company focuses on CNS disease treatments.
Read more →SUPNSupernus Announces First Quarter 2026 Financial Results
Supernus Pharmaceuticals reported strong financial results for Q1 2026, with total revenues of $207.7 million, a 39% increase from the previous year. The company's growth products saw a 56% revenue increase, driven by Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. A regulatory submission for a second supplier of ONAPGO is anticipated in Q3 2026, with potential approval by mid-2027. Despite an operating loss, the company maintains a positive outlook for the year.
Read more →SUPNSupernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Supernus Pharmaceuticals will report its first quarter 2026 financial results on May 5, 2026, after market close. A conference call will follow at 4:30 p.m. ET, hosted by CEO Jack Khattar and CFO Tim Dec. The call will allow for questions after their prepared remarks. A replay will be available on their Investor Relations website.
Read more →SUPN▲ +5.7%on this news
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
Supernus Pharmaceuticals reported record financial results for Q4 and full year 2025, highlighting significant revenue growth and strategic advancements. The company successfully acquired Sage Therapeutics and received FDA approval for ONAPGO, a treatment for Parkinson's disease. Looking ahead, Supernus aims to continue progress on its growth products and pipeline candidates in 2026.
Read more →SUPN▲ +5.1%on this newsshared move
Supernus Pharmaceuticals to Participate in March 2026Investor Conferences
Supernus Pharmaceuticals, Inc. announced its participation in March investor conferences, providing opportunities for investors to meet with management. The company focuses on developing treatments for central nervous system diseases and has a diverse portfolio that includes several approved therapies. Live webcasts of the presentations will be available on their website.
Read more →SUPNSupernus Pharmaceuticals to Participate in March Investor Conferences
Supernus Pharmaceuticals, Inc. has announced its participation in several March investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference. The management will engage with investors and provide updates on the company’s developments in central nervous system (CNS) therapies. Additionally, the company emphasizes its commitment to a diverse portfolio for treating various CNS diseases, while also acknowledging potential risks associated with future business performance and regulatory approvals.
Read more →SUPNSupernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on
Supernus Pharmaceuticals, Inc. has announced that it will report its fourth quarter and full year 2025 financial results on February 24, 2026. The announcement will be followed by a conference call hosted by key executives, providing an opportunity for investors to gain insights into the company's performance and future prospects. The company's focus remains on CNS diseases, and despite its diverse portfolio, it faces various risks concerning profitability and regulatory approvals that could impact its financial outlook.
Read more →SUPNSupernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Supernus Pharmaceuticals will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on December 8, 2025. CEO Jack A. Khattar will lead the presentation, highlighting the company's focus on CNS disease treatments. Investors can access a live audio webcast and arrange meetings with management during the conference.
Read more →SUPNSupernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
Supernus Pharmaceuticals announced that its CEO, Jack A. Khattar, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The event will be held in New York City and includes opportunities for investors to meet with company management. A live audio webcast will be available for those unable to attend in person, along with an archived replay following the conference. The company focuses on developing treatments for various central nervous system conditions.
Read more →SUPNSupernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
Supernus Pharmaceuticals will participate in the 2025 Jefferies Global Healthcare Conference in London. CEO Jack A. Khattar will engage in a fireside chat on November 17, 2025. Investors can arrange meetings with management and access a live audio webcast of the presentation. The company focuses on CNS disease treatments and has a diverse portfolio.
Read more →SUPN▼ -17.4%on this news
Supernus Announces Third Quarter 2025 Financial Results
Supernus Pharmaceuticals reported strong financial results for Q3 2025, driven by robust sales of its growth products, including Qelbree and GOCOVRI. The company also highlighted the successful launch of ONAPGO and provided an optimistic outlook for 2026. However, it faces challenges from generic competition affecting Trokendi XR and Oxtellar XR.
Read more →SUPNSupernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Supernus Pharmaceuticals will report its third quarter 2025 financial results on November 4, 2025. The announcement includes a conference call hosted by CEO Jack Khattar and CFO Tim Dec to discuss the results. A live webcast will be available, and participants can pre-register for the call. The company specializes in CNS disease treatments.
Read more →SUPNSupernus Pharmaceuticals to Participate in September Investor Conferences
Supernus Pharmaceuticals, Inc. announced its participation in several investor conferences in September. The company focuses on developing treatments for central nervous system diseases and encourages investors to arrange meetings with management. Presentations will be available via live audio webcast, with archived replays accessible for 60 days.
Read more →SUPNSupernus Announces Second Quarter 2025 Financial Results Net sales of Qelbree increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in
Supernus Pharmaceuticals has reported a positive second quarter for 2025, with Qelbree net sales increasing by 31% year-on-year and GOCOVRI sales also seeing a 16% rise. Total revenues for the quarter reached $165.5 million, slightly down from $168.3 million in Q2 2024. The company's acquisition of Sage Therapeutics is expected to enhance its offerings in neuropsychiatric treatments and drive future revenue growth. Despite an overall strong performance, there was a decline in operating earnings compared to the previous year.
Read more →SUPNSupernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Supernus Pharmaceuticals has completed its acquisition of Sage Therapeutics, enhancing its product portfolio with a significant fourth growth product. The acquisition is anticipated to be accretive in 2026, supported by expected cost synergies. Sage will operate as a wholly owned subsidiary of Supernus, with potential milestone payments tied to the performance of the product ZURZUVAE.
Read more →SUPNSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the Hart-Scott-Rodino waiting period for its acquisition of Sage Therapeutics. This marks a significant step towards finalizing the tender offer, which includes a cash payment and contingent value rights based on future sales of Sage's product, ZURZUVAE. The offer is set to expire on July 30, 2025, pending other conditions.
Read more →SUPNSupernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on
Supernus Pharmaceuticals plans to announce its financial results for the second quarter of 2025 on August 5, 2025, and will host a conference call to discuss these results. The company, focused on CNS disease treatments, expects to provide updates regarding its business performance. A live webcast of the call will be available on the company's Investor Relations website, along with a replay accessible for 60 days. The press release also outlines several risks associated with the company's ongoing acquisition negotiations and operational strategies.
Read more →SUPNSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Supernus Pharmaceuticals has announced a definitive agreement to acquire Sage Therapeutics for $8.50 per share in cash, totaling approximately $795 million. This acquisition will enhance Supernus's neuropsychiatry product portfolio by adding ZURZUVAE, the first FDA-approved oral treatment for postpartum depression. The deal is expected to close in the third quarter of 2025, pending regulatory approvals. Additionally, the acquisition includes contingent value rights based on ZURZUVAE's sales milestones.
Read more →SUPNSupernus to Participate in the 2025 Jefferies Global Healthcare Conference
Supernus Pharmaceuticals, Inc. will participate in the 2025 Jefferies Global Healthcare Conference, where CEO Jack A. Khattar will engage in a fireside chat. The event is scheduled for June 4, 2025, in New York City. Investors can arrange meetings with company management and access a live audio webcast of the presentation. The company focuses on CNS diseases and has a diverse product portfolio including treatments for ADHD, epilepsy, and other disorders.
Read more →SUPNSupernus Announces Paragraph IV ANDA Filings for Qelbree ROCKVILLE, MD
Supernus Pharmaceuticals announced receipt of Paragraph IV Notice Letters from third parties for viloxazine extended-release capsules (Qelbree). The company is reviewing these letters and plans to enforce its intellectual property rights aggressively, backed by several patents listed in the FDA's Orange Book. While this indicates market competition, it also raises concerns regarding potential revenue impacts from generic competition if successful.
Read more →SUPNSupernus Announces First Quarter 2025 Financial Results First quarter 2025 net sales of Qelbree increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI increased 16% t
Supernus Pharmaceuticals announced its first quarter 2025 financial results, showing a 44% increase in Qelbree net sales to $64.7 million compared to the previous year. The company also reported a 16% increase in GOCOVRI sales, contributing to total revenues of $149.8 million, a 4% rise from the same quarter in 2024. Despite these growth figures, Supernus recorded an operating loss of $(10.3) million, which was larger than last year's $(3.2) million loss. The company launched ONAPGO in April 2025, targeting adults experiencing motor fluctuations due to Parkinson's disease, with positive initial feedback from physicians.
Read more →SUPNSupernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on
Supernus Pharmaceuticals has announced that it will report its financial and business results for the first quarter of 2025 on May 6, 2025, after market close. The announcement includes a scheduled conference call at 4:30 p.m. ET, hosted by President and CEO Jack Khattar and CFO Tim Dec, for discussing these results. The event will also feature a question-and-answer session for participants. A live webcast will be available for those interested in following the meeting.
Read more →SUPNSupernus to Participate in Two Upcoming Investor Conferences
Supernus Pharmaceuticals, Inc. announced participation in two prominent investor conferences in March 2025. Jack Khattar, the President and CEO, will speak at the Barclays Global Healthcare Conference and the Jefferies Biotech on the Beach Summit. Investors can attend the live audio webcast of the fireside chat and arrange meetings with management. The company continues to focus on its portfolio for treating central nervous system diseases.
Read more →SUPNSupernus to Participate in the TD Cowen 45th Annual Health Care Conference
Supernus Pharmaceuticals, Inc. will participate in the TD Cowen 45th Annual Health Care Conference on March 3, 2025. Jack A. Khattar, the company's President and CEO, is scheduled for a fireside chat at the event. Investors can access a live audio webcast of the presentation and arrange meetings with company management. Supernus focuses on developing products for central nervous system diseases, showcasing its broad portfolio in the neuroscience sector.
Read more →SUPNSupernus Announces Fourth Quarter and Full Year 2024 Financial Results Fourth quarter 2024 net sales of Qelbree increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree inc
Supernus Pharmaceuticals reported significant financial growth for Q4 and full year 2024, with Qelbree sales increasing by 60% and full year operating earnings moving from a loss to a profit. Additionally, the FDA approval of ONAPGO for Parkinson's disease marks a key advancement for the company. However, there were notable declines in sales for some products, and the development of SPN-820 for treatment-resistant depression did not yield significant results in clinical trials. Overall, Supernus expects continued growth in 2025, bolstered by an expanding product pipeline.
Read more →SUPNSupernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms
Supernus Pharmaceuticals announced that its Phase 2b study of SPN-820 in adults with treatment-resistant depression failed to meet its primary endpoint of reducing depressive symptoms as measured by the MADRS total score. The trial did not show a statistically significant improvement when compared to placebo. Although the drug was well-tolerated with minimal adverse effects, the lack of efficacy could hinder future development. The company plans to analyze the trial data further and discuss the program's future with its development partner, Navitor Pharmaceuticals.
Read more →SUPNSupernus Pharmaceuticals to Host Conference Call and Webcast on
Supernus Pharmaceuticals, Inc. is scheduled to host a conference call on February 25, 2025, to discuss its fourth quarter and full year financial results for 2024. The call will feature President and CEO Jack Khattar along with Senior Vice President and CFO Tim Dec, followed by a Q&A session. The event will be accessible via live webcast on the company's Investor Relations website, with a replay available for 60 days post-event. Supernus focuses on treatments for central nervous system diseases, maintaining a diverse portfolio of approved products and ongoing development efforts.
Read more →SUPN▲ +7.1%on this news
Supernus Announces FDA Approval of ONAPGO (apomorphine hydrochloride) for Parkinson's Disease ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with a
Supernus Pharmaceuticals announced the FDA's approval of ONAPGO (apomorphine hydrochloride), the first subcutaneous infusion device for treating motor fluctuations in adults with advanced Parkinson's disease. This wearable device aims to provide continuous treatment to improve patients' quality of life. Clinical trials demonstrated significant efficacy in reducing OFF time and increasing GOOD ON time. ONAPGO is expected to be available in the U.S. by the second quarter of 2025, backed by a robust patient support program.
Read more →SUPNSupernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree , Including New Pharmacodynamic Data and Information for Breastfeeding Women
Supernus Pharmaceuticals announced that the FDA has approved an update to the label for its ADHD treatment Qelbree. The updated label includes new pharmacodynamic data and information regarding the transfer of Qelbree into breastmilk, which is noted as low. These changes aim to enhance understanding and support treatment decisions for users, particularly among breastfeeding women. Qelbree remains the first ADHD treatment to meet the post marketing requirements outlined in the FDA's 2019 guidance on Clinical Lactation Studies.
Read more →SUPNSupernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Supernus Pharmaceuticals, Inc. announced its participation at the 36th Annual Piper Sandler Healthcare Conference, where CEO Jack A. Khattar will engage in a discussion on December 4, 2024. The event occurs in New York City, and interested investors may schedule meetings with the company's management. A live audio webcast of the presentation will be available, along with an archived replay for 60 days, highlighting the company's focus on CNS disease treatment and investor engagement.
Read more →SUPNSupernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
Supernus Pharmaceuticals, Inc. will participate in the Jefferies London Healthcare Conference on November 20, 2024, where CEO Jack Khattar is set to engage in a fireside chat. The event aims to enhance investor relations and promote the company's focus on central nervous system (CNS) treatments. A live audio webcast of the presentation will be accessible to interested parties, with an archived version available for 60 days post-conference. Supernus's diverse CNS portfolio includes treatments for various CNS diseases, indicating their ongoing commitment to innovation in the field.
Read more →SUPNSupernus Announces Third Quarter 2024 Financial Results Net sales of Qelbree increased 68% in the third quarter of 2024, compared to the same period in 2023. Net sales of Qelbree of $62.4 million and $166.9 million in th
Supernus Pharmaceuticals reported a strong financial performance for the third quarter of 2024, with Qelbree net sales increasing by 68% compared to the same period last year. Total revenues reached $175.7 million, marking a 14% rise year-over-year. The company also raised its full-year revenue guidance, reflecting optimism about current growth. Additionally, Supernus is making advancements in its product pipeline, including the potential impact of SPN-820 for major depressive disorder, with results from ongoing studies expected in the near future.
Read more →SUPNSupernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Supernus Pharmaceuticals presented encouraging results from its open-label Phase 2a study of SPN-820 at Psych Congress 2024. The study, involving 40 adults with major depressive disorder, showed significant reductions in depressive symptoms, including a drastic 80% decrease in suicidal ideation. SPN-820 was well-tolerated, with mild to moderate adverse events reported and no severe adverse effects. The results suggest that SPN-820 could provide a rapid-onset, effective treatment option for patients suffering from depression.
Read more →SUPNSupernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tole
Supernus Pharmaceuticals announced positive results from its Phase 2a study of SPN-820 in adults with major depressive disorder. The study indicated a rapid and substantial decrease in depressive symptoms, with improvements evident at two hours and Day 10. SPN-820 showed a significant reduction in suicidal ideation, as well as good tolerability with few adverse events reported. The company expects to provide further insights from a subsequent Phase 2b study scheduled for completion in 2025.
Read more →SUPNSupernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
Supernus Pharmaceuticals has announced a webcast scheduled for October 17, 2024, to review data from an open-label Phase 2a study of SPN-820, intended for the treatment of major depressive disorder. The webcast will feature management's discussion of interim trial results, followed by a Q&A session. This event highlights the company's ongoing commitment to developing innovative treatments for central nervous system diseases.
Read more →SUPNDocument Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder ROCKVILLE, Md.
Supernus Pharmaceuticals, Inc. will hold a webcast on October 17, 2024, to discuss the interim data from its open-label Phase 2a study of SPN-820 for treating major depressive disorder. The event will include a presentation followed by a Q&A session to engage investors. This initiative highlights the company's commitment to developing novel treatments for CNS diseases.
Read more →SUPNSupernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Supernus Pharmaceuticals Inc. will participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit, scheduled for September 26, 2024. Jack Khattar, the company’s President and CEO, will engage in a virtual fireside chat at 8:40 a.m. ET. The event aims to highlight new developments in the treatment of central nervous system diseases. Investors and stakeholders can access a live webcast and a subsequent archived replay on the company's website.
Read more →SUPNSupernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
Supernus Pharmaceuticals is set to participate in the 2024 Wells Fargo Healthcare Conference on September 4, 2024. CEO Jack Khattar will engage in a fireside chat, highlighting the company's focus on treatments for central nervous system diseases. Interested investors can arrange meetings with management during the event. The company offers a diverse portfolio of approved CNS treatments and is developing new product candidates.
Read more →SUPNSupernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA PDUFA Target Action Date of
Supernus Pharmaceuticals announced that the FDA has accepted the resubmission of the New Drug Application (NDA) for its apomorphine infusion device, SPN-830, targeting the treatment of motor fluctuations in Parkinson's disease. The resubmission has been officially filed and is assigned a PDUFA target action date of February 1, 2025. This development is part of Supernus's broader strategy to develop products for CNS diseases, showcasing its commitment to innovative treatment approaches.
Read more →SUPNSupernus Announces Second Quarter 2024 Financial Results Net sales of Qelbree increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in the second
Supernus Pharmaceuticals, Inc. announced strong financial results for the second quarter of 2024, with Qelbree net sales increasing 92% to $59.4 million. Total revenues reached $168.3 million, a 24% increase over the previous year. The company raised its full-year guidance for total revenues and operating earnings, reflecting confidence in ongoing growth. Supernus also advanced its product pipeline, including resubmitting an NDA for SPN-830 for Parkinson’s disease and ongoing studies for SPN-820 and SPN-817.
Read more →SUPNSupernus Resubmits NDA for SPN-830 Apomorphine Infusion Device ROCKVILLE, Md.
Supernus Pharmaceuticals has resubmitted its New Drug Application (NDA) for the SPN-830 apomorphine infusion device, designed for the treatment of motor fluctuations in Parkinson's disease. The company is optimistic that it has adequately addressed the FDA's concerns raised in a previous Complete Response Letter. There were no safety or efficacy issues highlighted that could hinder approval. Supernus is committed to working closely with the FDA during the review process, intending to deliver this novel treatment to patients soon.
Read more →SUPNSupernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on
Supernus Pharmaceuticals, Inc. has announced that it will report its financial and business results for the second quarter of 2024 on August 6, 2024, after market closure. The call, hosted by CEO Jack Khattar and CFO Tim Dec, will be available for live questions and will also be accessible through a webcast. Supernus focuses on developing treatments for central nervous system (CNS) disorders and has a wide array of product candidates in its pipeline.
Read more →SUPNSupernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Supernus Pharmaceuticals, Inc. announced that its President and CEO, Jack Khattar, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024. This event highlights the company's continued engagement with investors and emphasizes its focus on developing treatments for central nervous system diseases. Investors are encouraged to arrange meetings with management during the conference, and a live audio webcast of the presentation will be available for wider access.
Read more →SUPNSupernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to ho
Supernus Pharmaceuticals announced promising interim results from its Phase 2a clinical study of SPN-817, a selective acetylcholinesterase inhibitor intended for the treatment of epilepsy. The interim analysis, conducted on 41 enrolled subjects, revealed median focal seizure reductions of 75% during the maintenance period and 86% during the open-label extension period. The study also indicated that SPN-817 showed an acceptable safety profile, with a low discontinuation rate due to adverse events. These findings may significantly contribute to the ongoing development and design of future studies related to SPN-817.
Read more →SUPNSupernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures ROCKVILLE, Md.
Supernus Pharmaceuticals, Inc. has announced a webcast scheduled for May 23, 2024, to review interim data from its open-label Phase IIa study of SPN-817, aimed at treating treatment-resistant seizures. This event will include a presentation of the trial results followed by a Q&A session. The company, which specializes in CNS diseases, emphasizes the significance of these findings in addressing unmet medical needs for patients with seizures.
Read more →SUPNSupernus Announces First Quarter 2024 Financial Results Net sales of Qelbree increased 75% to $45.1 million compared to first quarter 2023. Total revenues were $143.6 million. Total revenues excluding Trokendi XR and Oxt
Supernus Pharmaceuticals reported a strong financial performance for the first quarter of 2024, with net sales of its ADHD medication Qelbree jumping 75% year-over-year to $45.1 million. Overall total revenues reached $143.6 million, although this marks a decline from $153.8 million in the same period a year earlier, primarily due to a decrease in sales of Trokendi XR. Despite an operating loss of $3.2 million, the company reiterated its total revenue guidance for the year, projecting $580 million to $620 million. Furthermore, the progress in ongoing clinical trials, including new treatments for Parkinson's disease and depression, adds potential for future growth.
Read more →SUPNSupernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on
Supernus Pharmaceuticals will announce its financial results for the first quarter of 2024 on May 8, 2024. The report will be followed by a conference call at 4:30 p.m. ET, where executives will discuss the results and answer questions. The call will be accessible via a live webcast, and a replay will be available for 60 days afterward. Supernus specializes in developing treatments for central nervous system diseases, and the upcoming report is part of its ongoing commitment to transparency.
Read more →SUPN▼ -6.3%on this news
Supernus Provides Regulatory Update for SPN-830 ROCKVILLE, Md.
Supernus Pharmaceuticals has announced a regulatory update regarding SPN-830, an investigational apomorphine infusion device for treating motor fluctuations in Parkinson's disease. The FDA issued a Complete Response Letter, indicating the New Drug Application is not yet approvable in its current form. Specific areas needing further review include product quality and data from the device manufacturer. However, no clinical safety or efficacy issues were reported, and Supernus is committed to addressing the FDA's concerns for future resubmission.
Read more →SUPN▼ -6.3%on this news
Supernus Provides Regulatory Update for SPN-830
Supernus Pharmaceuticals announced that the FDA has issued a Complete Response Letter for its New Drug Application for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. The letter indicates that while the review cycle is complete, the application is not yet ready for approval. Specific issues regarding product quality and additional information from the device manufacturer need to be addressed before resubmission. No safety or efficacy problems were identified, and the company remains committed to bringing SPN-830 to market.
Read more →SUPNSupernus to Participate in the TD Cowen 44th Annual Healthcare Conference
Supernus Pharmaceuticals announced that its President and CEO, Jack Khattar, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on March 6, 2024. This participation aims to enhance dialogue with investors and stakeholders regarding the company's focus on CNS disease treatments. Live audio of the discussion will be available online, with an archived replay accessible for 60 days afterward. Supernus continues to develop innovative products in the CNS domain, addressing various conditions such as epilepsy and Parkinson's disease.
Read more →SUPNSupernus Announces Fourth Quarter and Full Year 2023 Financial Results Fourth quarter 2023 net sales of Qelbree increased 97% to $46.4 million compared to fourth quarter 2022 Full year 2023 net sales of Qelbree increased
Supernus Pharmaceuticals reported strong financial results for Q4 and full year 2023, with Qelbree net sales increasing by 97% to $46.4 million compared to the previous year. The company highlighted significant growth across its key products, particularly Qelbree and GOCOVRI, and provided guidance for 2024 revenues between $580 million to $620 million. However, Supernus also faced challenges with an operating loss of $(5.3) million and declining sales from Trokendi XR. The company anticipates several clinical milestones and the launch of SPN-830 later in 2024.
Read more →SUPNSupernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on
Supernus Pharmaceuticals has announced it will report its financial results for the fourth quarter and full year of 2023 on February 27, 2024. The announcement includes details about a conference call where the President and CEO, Jack Khattar, along with CFO Tim Dec, will discuss the results and take questions. This reflects the company's commitment to keeping investors informed about its financial performance and ongoing developments in the CNS treatment area.
Read more →SUPNSupernus Wins Infringement and Validity Case on Trokendi XR against Torrent ROCKVILLE, Md.
Supernus Pharmaceuticals, Inc. has announced that the United States District Court for the District of New Jersey ruled in its favor, declaring that Torrent Pharmaceuticals infringed upon Supernus' patents related to Trokendi XR. The court's decision also confirmed the validity of these patents, which bolsters Supernus' market position as they strive to protect their intellectual property. This legal victory provides an essential reinforcement for the company's commitment to safeguarding its innovative CNS treatments.
Read more →SUPNSupernus Announces Third Quarter 2023 Financial Results Raises full year 2023 adjusted operating earnings (non-GAAP) (1) guidance range to $95 million to $110 million from previous range of $75 million to $100 million To
Supernus Pharmaceuticals reported strong financial results for the third quarter of 2023, raising its full year adjusted operating earnings guidance to $95-$110 million. The company saw significant increases in net product sales for Qelbree and GOCOVRI, with Qelbree alone rising by 103% year-over-year. Despite a decline in overall net product sales attributable to Trokendi XR, the acceptance of the NDA resubmission for SPN-830 by the FDA signals positive pipeline advancements. Total revenues excluding Trokendi XR also showcased healthy growth, up 24% from the prior year, reflecting an overall strong market position.
Read more →SUPNSupernus to Participate in the Jefferies London Healthcare Conference
Supernus Pharmaceuticals, Inc. is set to participate in the Jefferies London Healthcare Conference on November 15, 2023. CEO Jack Khattar will engage in a fireside chat that aims to provide insights into the company's operations and product development focus on central nervous system diseases. The event underscores Supernus's commitment to increasing engagement with investors and showcasing their advancements in treatments for conditions such as epilepsy and Parkinson’s disease. A live audio webcast will be available for those unable to attend in person.
Read more →SUPNSupernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on
Supernus Pharmaceuticals announced that it will report its financial results for the third quarter of 2023 on November 8, 2023. Following the earnings report, a conference call will be hosted by CEO Jack Khattar and CFO Tim Dec to discuss the results and answer investor questions. Investors can access the call live and a replay will be available for 60 days on the company’s website. Supernus specializes in developing products for central nervous system diseases, underscoring its commitment to this therapeutic area.
Read more →SUPNxA9; 2023 Supernus Pharmaceuticals, Inc. All Rights Reserved. Supernus Pharmaceuticals R&D Day
Supernus Pharmaceuticals conducted an R&D Day, highlighting its product candidates SPN-443 and SPN-817. The presentation covered the compounds' mechanisms of action and their potential impact on conditions such as narcolepsy and refractory focal seizures. Market research indicated a positive perception of these candidates among adult treaters, while pediatric treaters exhibited caution in adoption. The company acknowledged the inherent risks associated with its operations and the uncertainties in its business strategy moving forward.
Read more →SUPNSupernus Resubmits NDA for SPN-830 Apomorphine Infusion Device ROCKVILLE, MD
Supernus Pharmaceuticals has resubmitted its New Drug Application for the SPN-830 apomorphine infusion device, aimed at continuous treatment for motor fluctuations in Parkinson's disease. This move comes after the company addressed concerns raised in a prior Complete Response Letter from the FDA. The resubmission signals Supernus's commitment to providing a novel, less invasive therapy for patients. The FDA's review process will be closely monitored by the company as they seek to bring the product to market.
Read more →SUPNSupernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
Supernus Pharmaceuticals, Inc. will host a webcast of its R&D Day on October 18, 2023, in New York City. The event will feature presentations from its senior management team highlighting the company's pipeline, particularly new clinical candidates SPN-820, SPN-821, and SPN-817. Additionally, a key opinion leader will discuss current treatment paradigms and areas of unmet medical needs. Participants can register for the webcast and submit questions prior to the event.
Read more →SUPNSupernus Announces New Qelbree Data Showing Improvement in ADHD Symptoms
Supernus Pharmaceuticals has announced new data from a Phase IV study demonstrating the efficacy and safety of Qelbree for treating ADHD. The results indicate that Qelbree, when added to stimulant medication, significantly improves symptoms in pediatric patients. Additionally, long-term data show sustained improvements in adults with ADHD. However, the treatment comes with potential side effects, including increased risk of suicidal thoughts and discontinuation due to adverse events. The data were presented at Psych Congress 2023.
Read more →SUPNSupernus to Participate in the Wells Fargo Healthcare Conference
Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO, will participate in the upcoming 2023 Wells Fargo Healthcare Conference on September 6, 2023. The conference, held in Boston, offers investors opportunities to arrange meetings with company management. Supernus focuses on developing treatments for central nervous system diseases, with a diverse portfolio including products for conditions such as epilepsy and Parkinson's disease. A live audio webcast of the presentation will be available on the company's website, with a replay accessible for 60 days post-conference.
Read more →SUPNBethany L. Sensenig Joins Supernus' Board of Directors ROCKVILLE, MD
Supernus Pharmaceuticals has announced the appointment of Bethany L. Sensenig to its Board of Directors, expanding the board to seven members. Ms. Sensenig, who has extensive experience in the biopharmaceutical industry, previously served as Chief Financial Officer and Interim Chief Executive Officer at 9 Meters Biopharma. Her strategic insights are expected to play a crucial role as Supernus continues to develop products for central nervous system diseases. This addition aligns with the company's goals of enhancing its commercial operations and advancing its product pipeline.
Read more →SUPNSupernus Announces Second Quarter 2023 Financial Results Qelbree net product sales growth of 179% and 193% in the second quarter and first six months of 2023, respectively, compared to the same periods in 2022 - $31.0 mi
Supernus Pharmaceuticals reported substantial growth in Qelbree sales, with a 179% increase in net sales for the second quarter of 2023 compared to the same quarter of 2022. The company's total revenues rose by 25% for the first half of 2023, driven by the performance of Qelbree and GOCOVRI. However, Supernus also faced challenges, including an operating loss of $12.4 million, a decline in overall net product sales, and decreased earnings compared to the previous year. The company plans to resubmit the New Drug Application for SPN-830 in Q4 2023 and continues to develop several other candidates in its pipeline.
Read more →SUPNSupernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on
Supernus Pharmaceuticals, Inc. announced the upcoming release of its second quarter 2023 financial results, scheduled for August 8, 2023. The company's President and CEO, Jack Khattar, along with Senior VP and CFO, Tim Dec, will host a conference call to discuss these results. The event will be accessible via a live webcast and will allow for participant questions. Supernus is known for its focus on treatments for central nervous system diseases.
Read more →SUPNSupernus to Participate in the Jefferies Healthcare Conference
Supernus Pharmaceuticals, Inc. announced that Jack Khattar, the company's President and CEO, will participate in a fireside chat at the Jefferies Healthcare Conference on June 7, 2023. This event presents a platform for the company to engage with investors and discuss its portfolio in central nervous system (CNS) treatments. Supernus emphasizes its commitment to developing innovative products for a variety of CNS conditions. Investors may access a live audio webcast of the presentation and an archived replay will be available afterward.
Read more →SUPNSupernus Announces First Quarter 2023 Financial Results First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 - Qelbree net product sales of $25.8 million, compared to $8.3
Supernus Pharmaceuticals reported its financial results for the first quarter of 2023, achieving total revenues of $153.8 million, a marginal increase over the previous year's $152.5 million. The company experienced strong sales growth for Qelbree, which reached $25.8 million, and GOCOVRI, which totaled $26.0 million. Despite generic competition impacting Trokendi XR's sales, Supernus raised its financial guidance for the remainder of the year. Additionally, progress continues on their product pipeline, including the resubmission of the New Drug Application for SPN-830 expected later this year.
Read more →SUPNSupernus to Present at the Bank of America 2023 Health Care Conference
ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President
Read more →SUPNSupernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on
Supernus Pharmaceuticals, Inc. announced it will disclose its financial and business results for the first quarter of 2023 on May 9, 2023. Following the announcement, a conference call will be held, providing an opportunity for stakeholders to engage and ask questions. The call will be accessible via webcast, and a replay will be available on the company's Investor Relations website afterwards. Supernus focuses on CNS diseases, highlighting its diverse portfolio and ongoing innovation.
Read more →SUPNSupernus Announces Repayment of Convertible Notes
ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that it has paid the total
Read more →SUPNSupernus Announces Repayment of Convertible Notes ROCKVILLE, Md.
Supernus Pharmaceuticals, Inc. has successfully repaid its 0.625% Convertible Senior Notes due 2023, totaling $402.5 million, along with $1.3 million in interest. This repayment was primarily financed with available cash on hand and partially through a credit line. As a result, the 2023 Notes are now no longer outstanding, which enhances the company's financial position and reduces liabilities going forward.
Read more →SUPNSupernus to Present at the Cowen 43rd Annual Health Care Conference
ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, Presiden
Read more →SUPNSupernus Announces Fourth Quarter and Full Year 2022 Financial Results Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021 Fourth quarter 2022 Qelbree net product sales of $23.6 mil
Supernus Pharmaceuticals reported strong financial results for the fourth quarter and full year of 2022, with total revenues reaching $667.2 million, a 15% increase compared to 2021. Notably, Qelbree net product sales rose significantly, exceeding $23.6 million in Q4. The company anticipates approximately 30% revenue growth in 2023, despite facing challenges with the impending loss of exclusivity for Trokendi XR. The financial performance reflects the successful transition to high-growth products, although operating earnings have decreased due to additional costs linked to acquisitions.
Read more →SUPNSupernus Enters Into $150 Million Credit Facility
ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it entered into a credit lin
Read more →SUPNSupernus Enters Into $150 Million Credit Facility ROCKVILLE, MD
Supernus Pharmaceuticals, Inc. has announced a new credit facility providing an unsecured line of credit up to $150 million with UBS Bank USA. This agreement is intended to enhance the company's financial flexibility and strength. The funding will support its ongoing development and commercialization efforts for treatments related to central nervous system diseases. CEO Jack Khattar highlighted the importance of this credit line for the company’s future growth and operational strategies.
Read more →SUPNSupernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on
Supernus Pharmaceuticals, Inc. announced it will release its financial results for the fourth quarter and full year of 2022 on February 28, 2023. The conference call will be hosted by President and CEO Jack Khattar and Senior VP and CFO Tim Dec at 4:30 p.m. ET. Stakeholders can access a live webcast on the investor relations website following the market close, highlighting the company's commitment to updates on its financial health and business developments.
Read more →SUPNSupernus to Present at the Piper Sandler 34th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President
Read more →SUPNSupernus to Present at Two November Healthcare Conferences
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President
Read more →SUPNSupernus Announces Third Quarter 2022 Financial Results Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021 Increasing full year 2022 operating earnings guidance to $35 mill
Supernus Announces Third Quarter 2022 Financial Results Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021 Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previo
Read more →SUPNSupernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022 ROCKVILLE, Md., October 25, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products
Read more →SUPNSupernus Provides Regulatory Update on SPN-830
ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Adm
Read more →SUPNSupernus Provides Regulatory Update on SPN-830 ROCKVILLE, Md.
Supernus Provides Regulatory Update on SPN-830 ROCKVILLE, Md., October 10, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced
Read more →SUPNSupernus to Present at the 2022 Wells Fargo Healthcare Conference
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President
Read more →SUPNSupernus Announces Second Quarter 2022 Financial Results Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021 Second quarter 2022 GAAP operating earnings of $11.3 million s
Supernus Announces Second Quarter 2022 Financial Results Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021 Second quarter 2022 GAAP operating earnings of $11.3 million second quarter 2022 non-GAAP operating earnings of $37.6 mi
Read more →SUPNSupernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022 ROCKVILLE, Md., July 25, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for
Read more →SUPNSupernus Pharmaceuticals, Inc. All Rights Reserved. 1 Supernus Pharmaceuticals Jefferies Healthcare Conference June 2022 2022 Supernus Pharmaceuticals, Inc. All Rights Reserved. Safe Harbor Statement This presentation an
First - in - class selective brain mTORC1 activator Directly activates mTORC1 enhancing synaptic activity and cellular metabolism in the brain Early efficacy signal on HAMD - 6 scale in TRD patients Rapid onset of action (signal at 2 hours) Meaningful effect sizes (>0.4 through 3
Read more →SUPNSupernus Announces First Quarter 2022 Financial Results First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021 First quarter 2022 net earnings and diluted earnings per share (G
Supernus Announces First Quarter 2022 Financial Results First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021 First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectively First qua
Read more →SUPNSupernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022 ROCKVILLE, Md., May 2, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the t
Read more →SUPNSupernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to r
Read more →SUPNSupernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the
Supernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN
Read more →SUPNSupernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results Annual Report on Form 10-K filed on
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results Annual Report on Form 10-K filed on April 13, 2022 Reiterates full year 2022 financial guidance provided on February 28, 2022 and reiterated on April 4, 2022 ROCKVILLE, Md., April 13, 2022 - Sup
Read more →SUPNSupernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance ROCKVILLE, Md.
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance ROCKVILLE, Md., April 4, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of
Read more →SUPNSupernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance ROCKVILLE, Md.
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance ROCKVILLE, Md., March 17, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the
Read more →SUPNSupernus to Participate in Annual Cowen Health Care Conference
ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, Presiden
Read more →SUPNSupernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results Preliminary full year 2021 total revenues were $579.8 million an 11% increase compared to $520.4 million in 2020 SPN-830 (apomorphine inf
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results Preliminary full year 2021 total revenues were $579.8 million an 11% increase compared to $520.4 million in 2020 SPN-830 (apomorphine infusion device) NDA accepted for review by FDA PDUFA date ea
Read more →SUPNSupernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on
Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022 ROCKVILLE, Md., February 22, 2022 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializi
Read more →SUPNSupernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it received notice from
Read more →SUPNSupernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals Acquisition strengthens Parkinson's disease portfolio and diversifies revenue and cash flow ROCKVILLE, MD
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals Acquisition strengthens Parkinson's disease portfolio and diversifies revenue and cash flow ROCKVILLE, MD, November 24, 2021 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has s
Read more →SUPNSupernus Pharmaceuticals Targeted in Ransomware Incident The attack had no significant impact on the business and did not cause any significant disruption to Company's operations No ransom payments have been made by the
Supernus Pharmaceuticals Targeted in Ransomware The attack had no significant impact on the business and did not cause any significant disruption to Company's operations No ransom payments have been made by the Md., Nov. 24, 2021 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUP
Read more →SUPNSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharm
Read more →SUPNSupernus to Participate in Annual Piper Sandler Healthcare Conference
ROCKVILLE, Md., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s managemen
Read more →SUPNSupernus to Participate in Upcoming November Investor Conferences
ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s managemen
Read more →SUPN▲ +5.1%on this news
Supernus Announces Third Quarter 2021 Financial Results Total revenues for the first nine months of 2021 were $420.7 million a 12% increase compared to $376.8 million in the first nine months of 2020 Third quarter 2021 t
Supernus Announces Third Quarter 2021 Financial Results Total revenues for the first nine months of 2021 were $420.7 million a 12% increase compared to $376.8 million in the first nine months of 2020 Third quarter 2021 total revenues were $148.5 million, a 4% decrease compared
Read more →SUPNSupernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on
Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 ROCKVILLE, Md., October 27, 2021 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatmen
Read more →SUPN▲ +7.8%on this news· ran to +18% by day 3
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio and EMERYVILLE, CA, October 11, 2021 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agreement for S
Read more →SUPNSupernus Announces Qelbree sNDA for Adult Indication Accepted for Review by
Supernus Announces Qelbree sNDA for Adult Indication Accepted for Review by FDA ROCKVILLE, Md., September 2, 2021 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous s
Read more →SUPNSupernus to Participate in Upcoming September Investor Conferences
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s manageme
Read more →SUPNSupernus Announces Second Quarter 2021 Financial Results Second quarter 2021 total revenues of $141.3 million, a 12% increase compared to 2020 Qelbree launched in the U.S. for pediatric ADHD at the end of May 2021 Qelbre
Supernus Announces Second Quarter 2021 Financial Results Second quarter 2021 total revenues of $141.3 million, a 12% increase compared to 2020 Qelbree launched in the U.S. for pediatric ADHD at the end of May 2021 Qelbree sNDA for adult ADHD submitted to the FDA SPN-830 (apom
Read more →SUPNSupernus to Host Second Quarter 2021 Financial Results Conference Call ROCKVILLE, Md.
Supernus to Host Second Quarter 2021 Financial Results Conference Call ROCKVILLE, Md., July 22, 2021 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) d
Read more →SUPNSupernus to Present at Jefferies Virtual Healthcare Conference
ROCKVILLE, Md., May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President
Read more →SUPNQelbree (viloxazine extended-release capsules), a new non-controlled substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age Qelbree has proven efficacy in ADHD, with improvement in sym
Qelbree (viloxazine extended-release capsules), a new non-controlled substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age ROCKVILLE, MD., May 24, 2021 -- Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on de
Read more →SUPNSupernus Announces First Quarter 2021 Financial Results First quarter 2021 total revenues of $130.9 million, a 38% increase compared to 2020 Qelbree approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2
Supernus Announces First Quarter 2021 Financial Results First quarter 2021 total revenues of $130.9 million, a 38% increase compared to 2020 Qelbree approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2 2021 Qelbree sNDA submission for adult ADHD anticipated
Read more →SUPNSupernus Announces Paragraph IV ANDA Filing for XADAGO
ROCKVILLE, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Newron Pharmaceuticals S
Read more →SUPNSupernus Announces Paragraph IV ANDA Filing for
Supernus Announces Paragraph IV ANDA Filing for XADAGO ROCKVILLE, MD, May 4, 2021 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today anno
Read more →SUPNSupernus to Host First Quarter 2021 Financial Results Conference Call ROCKVILLE, Md.
Supernus to Host First Quarter 2021 Financial Results Conference Call ROCKVILLE, Md., April 27, 2021 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) d
Read more →SUPNSupernus Announces FDA Approval of Qelbree (SPN-812) for the Treatment of ADHD Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make
Supernus Announces FDA Approval of Qelbree (SPN-812) for the Treatment of ADHD ROCKVILLE, MD., April 2, 2021 -- Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous syste
Read more →SUPNSupernus to Present at Cowen Healthcare Conference
ROCKVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President an
Read more →SUPNSupernus Announces Fourth Quarter and Full Year 2020 Financial Results Full year 2020 total revenues of $520.4 million, a 32% increase compared to 2019 Full year 2020 operating earnings of $173.7 million, a 17% increase
Supernus Announces Fourth Quarter and Full Year 2020 Financial Results Full year 2020 total revenues of $520.4 million, a 32% increase compared to 2019 Full year 2020 operating earnings of $173.7 million, a 17% increase compared to 2019 SPN-812 NDA assigned an early April 2021
Read more →SUPNSupernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call ROCKVILLE, Md.
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call ROCKVILLE, Md., February 23, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nerv
Read more →SUPNSupernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA ROCKVILLE, Md., February 22, 2021 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervou
Read more →SUPNSupernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients ROCKVILLE, Md.
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients ROCKVILLE, Md., February 8, 2021 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment o
Read more →SUPNSupernus to Present at J.P. Morgan 39th Annual Healthcare Conference
ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management w
Read more →SUPNSupernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD Met primary endpoint with robust statistical significance Showed efficacy on both hyperactivity impulsivity and inattention subscal
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD Met primary endpoint with robust statistical significance Showed efficacy on both hyperactivity impulsivity and inattention subscales with statistical significance Showed statistically sig
Read more →SUPNSupernus to Present at Two November Investor Conferences
ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management w
Read more →SUPNSupernus Provides Regulatory Update for SPN-812 and SPN-830 ROCKVILLE, Md.
Supernus Provides Regulatory Update for SPN-812 and SPN-830 ROCKVILLE, Md., November 09, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t
Read more →SUPNSupernus Provides Regulatory Updates for SPN-812 and SPN-830
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812
Read more →SUPNSupernus Announces Third Quarter 2020 Financial Results Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 million Q3 2020 operating earnings of $56.1 mil
Supernus Announces Third Quarter 2020 Financial Results Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 million Q3 2020 operating earnings of $56.1 million On track to initiate commercial launch of SPN-812 in
Read more →SUPNSupernus to Host Third Quarter Results Earnings Conference Call ROCKVILLE, Md.
Supernus to Host Third Quarter Results Earnings Conference Call ROCKVILLE, Md., October 27, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases
Read more →SUPNSupernus to Host Third Quarter 2020 Financial Results Conference Call
ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to rep
Read more →SUPNSupernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer Greg Patrick to Retire as Chief Financial Officer ROCKVILLE, Md.
Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer Greg Patrick to Retire as Chief Financial Officer ROCKVILLE, Md., October 5, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products
Read more →SUPNSupernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson's Disease Who Have Failed Two Treatments ROCKVILLE, Md.
Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson's Disease Who Have Failed Two Treatments ROCKVILLE, Md., September 14, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and co
Read more →SUPNSupernus to Present at the Morgan Stanley 18 th Annual Global Healthcare Conference ROCKVILLE, Md.
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference ROCKVILLE, Md., September 9, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous s
Read more →SUPNSupernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management
Read more →SUPNSupernus to Present at the Wells Fargo Virtual Health Care Conference ROCKVILLE, Md.
Supernus to Present at the Wells Fargo Virtual Health Care Conference ROCKVILLE, Md., September 2, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) d
Read more →SUPNSupernus Announces Second Quarter 2020 Financial Results Total revenue of $126.7 million, including net product sales of $89.7 million for Trokendi XR , $23.7 million for Oxtellar XR , and $10.6 million for the acquired
Supernus Announces Second Quarter 2020 Financial Results Total revenue of $126.7 million, including net product sales of $89.7 million for Trokendi XR , $23.7 million for Oxtellar XR , and $10.6 million for the acquired Parkinson's disease (PD) products Operating earnings of $4
Read more →SUPNSupernus Announces Preliminary Second Quarter 2020 Revenue Second quarter total revenue is estimated to be $126.7 million, a 21% increase over 2019 Net product sales of Trokendi XR and Oxtellar XR are estimated to be $11
Supernus Announces Preliminary Second Quarter 2020 Revenue Second quarter total revenue is estimated to be $126.7 million, a 21% increase over 2019 Net product sales of Trokendi XR and Oxtellar XR are estimated to be $113.4 million, an 11% increase over 2019 Completed acquisit
Read more →SUPNSupernus Sues Apotex for Infringement of Oxtellar XR Patents ROCKVILLE, Md.
Supernus Sues Apotex for Infringement of Oxtellar XR Patents ROCKVILLE, Md., June 26, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, anno
Read more →SUPNSupernus Completes Acquisition of CNS Portfolio from US WorldMeds Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline ROCKVILLE, Md.
Supernus Completes Acquisition of CNS Portfolio from US WorldMeds Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline ROCKVILLE, Md., June 9, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a phar
Read more →SUPNSupernus to Present at the Jefferies Virtual Health Care Conference ROCKVILLE, Md.
Supernus to Present at the Jefferies Virtual Health Care Conference ROCKVILLE, Md., May 27, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases
Read more →SUPNSupernus Announces Paragraph IV ANDA Filing for Oxtellar
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR ROCKVILLE, Md., May 15, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today
Read more →SUPNSupernus Announces First Quarter 2020 Financial Results First quarter total revenue of $95.0 million, an 11% increase over 2019 First quarter net product sales of $92.5 million, an 11% increase over 2019 First quarter op
Supernus Announces First Quarter 2020 Financial Results First quarter total revenue of $95.0 million, an 11% increase over 2019 First quarter net product sales of $92.5 million, an 11% increase over 2019 First quarter operating earnings of $29.0 million, a 14% increase over 20
Read more →SUPNSupernus Announces First Quarter 2020 Financial Results
First quarter total revenue of $95.0 million, an 11% increase over 2019 First quarter net product sales of $92.5 million, an 11% increase over 2019 First quarter operating earnings of $29.0 million, a 14% increase over 2019 On track for launch of SPN-812 at the end of 2020, pe
Read more →SUPNSupernus to Acquire CNS Portfolio from US WorldMeds Expands and strengthens neurology portfolio with three marketed CNS products and late-stage pipeline Diversifies revenue and operating cash flow base with 2019 net sale
Supernus to Acquire CNS Portfolio from US WorldMeds Expands and strengthens neurology portfolio with three marketed CNS products and late-stage pipeline Diversifies revenue and operating cash flow base with 2019 net sales of approximately $150 million and operating earnings of
Read more →SUPNSupernus to Host First Quarter Results Earnings Conference Call ROCKVILLE, Md.
Supernus to Host First Quarter Results Earnings Conference Call ROCKVILLE, Md., April 24, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases,
Read more →SUPNSupernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138 Companies to Collaborate on Phase II Development for NV-5138 in Depression NV-5138 is a Novel First-in-Class Activ
Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138 Companies to Collaborate on Phase II Development for NV-5138 in Depression NV-5138 is a Novel First-in-Class Activator of mTORC1 Supernus Receives Exclusive Option to Lice
Read more →SUPNSupernus Provides Business Update
ROCKVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provides a business update related to th
Read more →SUPNSupernus Provides Business Update ROCKVILLE, Md.
Supernus Provides Business Update ROCKVILLE, Md., March 30, 2020 -- Supernus Pharmaceuticals, Inc. (Nasdaq SUPN), a pharmaceutical company company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provides a busi
Read more →SUPNSupernus Announces Fourth Quarter and Full Year 2019 Financial Results Fourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively. Fourth quarter and full year 2019 net product sal
Supernus Announces Fourth Quarter and Full Year 2019 Financial Results - Fourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively. - Fourth quarter and full year 2019 net product sales of $97.9 million and $383.4 million, respectively
Read more →SUPNSupernus to Present at the 2020 Cowen Health Care Conference
ROCKVILLE, Md., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management w
Read more →SUPNSupernus Announces Fourth Quarter and Full Year 2019 Financial Results
Fourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively. Fourth quarter and full year 2019 net product sales of $97.9 million and $383.4 million, respectively. Fourth quarter and full year 2019 operating earnings of $40.8 million and $
Read more →SUPNSupernus to Host Fourth Quarter and Full Year 2019 Results Earnings Conference Call ROCKVILLE, Md.
Supernus to Host Fourth Quarter and Full Year 2019 Results Earnings Conference Call ROCKVILLE, Md., February 11, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous
Read more →SUPNSupernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD SPN-812 (viloxazine hydrochloride), a once-daily novel serotonin norepinephrine modulating agent (SNMA), demonstr
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD SPN-812 (viloxazine hydrochloride), a once-daily novel serotonin norepinephrine modulating agent (SNMA), demonstrates a reduction in ADHD-RS-5 total score as early as Week
Read more →SUPNSupernus to Present at the 2020 J.P. Morgan Healthcare Conference ROCKVILLE, Md.
Supernus to Present at the 2020 J.P. Morgan Healthcare Conference ROCKVILLE, Md., January 8, 2020 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disea
Read more →SUPNSupernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients ROCKVILLE, Md.
Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients ROCKVILLE, Md., December 9, 2019 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercial
Read more →SUPNSupernus Submits New Drug Application for SPN-812 for the Treatment of ADHD SPN-812 (viloxazine hydrochloride), a novel serotonin norepinephrine modulating agent (SNMA) ROCKVILLE, Md.
Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD SPN-812 (viloxazine hydrochloride), a novel serotonin norepinephrine modulating agent (SNMA) ROCKVILLE, Md., November 11, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical compan
Read more →SUPNSupernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients Total revenue of $102.1 million , compared to $103.0 mi
Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients ROCKVILLE, Md., November 5, 2019 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focuse
Read more →SUPNSupernus to Host Third Quarter 2019 Earnings Conference Call ROCKVILLE, Md.
Supernus to Host Third Quarter 2019 Earnings Conference Call ROCKVILLE, Md., October 24, 2019 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases,
Read more →SUPNSupernus to Present at the 2019 Cantor Global Healthcare Conference ROCKVILLE, Md.
Supernus to Present at the 2019 Cantor Global Healthcare Conference ROCKVILLE, Md., September 25, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disea
Read more →SUPNSupernus to Present at Two September Healthcare Conferences ROCKVILLE, Md.
Supernus to Present at Two September Healthcare Conferences ROCKVILLE, Md., August 26, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today
Read more →SUPNSupernus Announces Second Quarter 2019 Financial Results Total revenue of $104.7 million , a 5.2% increase over 2018 Net product sales of $102.4 million , a 5.5% increase over 2018 Operating earnings of $42.6 million , a
Supernus Announces Second Quarter 2019 Financial Results ROCKVILLE, Md., August 6, 2019 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today
Read more →SUPNSupernus to Host Second Quarter 2019 Earnings Conference Call ROCKVILLE, Md.
Supernus to Host Second Quarter 2019 Earnings Conference Call ROCKVILLE, Md., July 23, 2019 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, to
Read more →SUPNSupernus to Present at the Jefferies 2019 Global Healthcare Conference ROCKVILLE, Md.
Supernus to Present at the Jefferies 2019 Global Healthcare Conference ROCKVILLE, Md., May 29, 2019 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, to
Read more →SUPNSupernus Announces First Quarter 2019 Financial Results Total revenue of $85.5 million and net product sales of $83.1 million. Net product sales compare to $89.1 million in 2018 and were adversely impacted by approximate
Supernus Announces First Quarter 2019 Financial Results Total revenue of $85.5 million and net product sales of $83.1 million. Net product sales compare to $89.1 million in 2018 and were adversely impacted by approximately $10 million in channel inventory reduction in the first
Read more →SUPNSupernus to Host First Quarter 2019 Earnings Conference Call ROCKVILLE, Md.
Supernus to Host First Quarter 2019 Earnings Conference Call ROCKVILLE, Md., April 24, 2019 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, to
Read more →SUPNSupernus Announces Webcast of Investor Day on
Supernus Announces Webcast of Investor Day on ROCKVILLE, Md., April 1, 2019 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it wi
Read more →SUPNSupernus Announces Webcast of Investor Day on April 16, 2019
ROCKVILLE, Md., April 01, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it will host and webcast an Inv
Read more →SUPNSupernus Announces P304 Phase III Data Confirming Positive Results from Previous Three Phase III Studies on SPN-812 in ADHD
400 mg dose reached statistical significance compared to placebo, consistent with previous Phase III studies: • Change versus baseline in ADHD Rating Scale 5, p-value = 0.0082 • Effect size of 0.66 • CGI-I secondary endpoint, p-value = 0.0051 • Hyperactivity/Impulsivity subsc
Read more →SUPNSupernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with
Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD ROCKVILLE, Md., March 27, 2019 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for
Read more →SUPNSupernus to Present at the 2019 Cowen Health Care Conference ROCKVILLE, Md.
Supernus to Present at the 2019 Cowen Health Care Conference ROCKVILLE, Md., March 6, 2019 Supernus Pharmaceuticals, Inc. (NASADQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today annou
Read more →SUPNSupernus Announces Record Full Year 2018 Financial Results Fourth quarter 2018 total revenue of $115.9 million, a 31% increase over 2017, and fourth quarter 2018 net product sales of $113.5 million, a 32% increase over 2
Supernus Announces Record Full Year 2018 Financial Results Fourth quarter 2018 total revenue of $115.9 million, a 31% increase over 2017, and fourth quarter 2018 net product sales of $113.5 million, a 32% increase over 2017. Fourth quarter 2018 operating earnings of $39.9 milli
Read more →SUPNSupernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call ROCKVILLE, Md.
Supernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call ROCKVILLE, Md., February 12, 2019 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
Read more →SUPNSupernus to Present at the 2019 J.P. Morgan Healthcare Conference
ROCKVILLE, Md., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will pr
Read more →SUPNSupernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD Met primary endpoint with robust statistical significance Third positive Phase III study for SPN-812 in patients with ADHD Sho
Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD Met primary endpoint with robust statistical significance Third positive Phase III study for SPN-812 in patients with ADHD Showed efficacy on both hyperactivity/impulsivity and inatte
Read more →SUPNSupernus Announces FDA Approval of sNDA to Expand Oxtellar XR Label to Include Monotherapy ROCKVILLE, Md.
Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR Label to Include Monotherapy ROCKVILLE, Md., December 14, 2018 Supernus Pharmaceuticals, Inc. (NASADQ: SUPN) announced today that the United States Food and Drug Administration (FDA) has approved the Company s supplem
Read more →SUPNSupernus Announces Positive Results from Two Phase III Studies For SPN-812 in Children with ADHD
Each study, P301 and P303, met primary endpoint with robust statistical significance Each study showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significance P301 study showed statistically significant onset of action as early as week
Read more →SUPNSupernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with
Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD ROCKVILLE, Md., December 5, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for
Read more →SUPNSupernus to Present at Three November Healthcare Conferences ROCKVILLE, Md.
Supernus to Present at Three November Healthcare Conferences ROCKVILLE, Md., November 7, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today an
Read more →SUPNSupernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue Total revenue of $103.0 million, a 28% increase over 2017 Net product sales of $100.2 million, a 28% increase over 2017 Operating earni
Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue Total revenue of $103.0 million, a 28% increase over 2017 Net product sales of $100.2 million, a 28% increase over 2017 Operating earnings of $37.5 million, a 68% increase over 2017 Diluted
Read more →SUPNSupernus to Host Third Quarter 2018 Earnings Conference Call ROCKVILLE, Md.
Supernus to Host Third Quarter 2018 Earnings Conference Call ROCKVILLE, Md., October 24, 2018 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS)
Read more →SUPNSupernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference ROCKVILLE, Md.
Supernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference ROCKVILLE, Md., September 20, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central ner
Read more →SUPNSupernus to Acquire Biscayne Neurotherapeutics Adds Phase 1 Novel Epilepsy Development Program Rockville, Md.
Supernus to Acquire Biscayne Neurotherapeutics Adds Phase 1 Novel Epilepsy Development Program Rockville, Md., September 13, 2018 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of ce
Read more →SUPNSupernus to Acquire Biscayne Neurotherapeutics
Adds Phase 1 Novel Epilepsy Development Program ROCKVILLE, Md., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases
Read more →SUPNSupernus Wins Appeal on Oxtellar XR against TWi Second Appeal Win against Generic Filers ROCKVILLE, Md.
Supernus Wins Appeal on Oxtellar XR against TWi Second Appeal Win against Generic Filers ROCKVILLE, Md., September 6, 2018 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central n
Read more →SUPNSupernus Wins Appeal on Oxtellar XR against TWi
Second Appeal Win against Generic Filers ROCKVILLE, Md., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, toda
Read more →SUPNSupernus to Present at September 2018 Wells Fargo Healthcare Conference ROCKVILLE, Md.
Supernus to Present at September 2018 Wells Fargo Healthcare Conference ROCKVILLE, Md., August 29, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous syste
Read more →SUPNSupernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue Total revenue of $99.5 million, a 31% increase over 2017 Net product sales of $97.0 million, a 32% increase over 2017 Operating earnin
Supernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue Total revenue of $99.5 million, a 31% increase over 2017 Net product sales of $97.0 million, a 32% increase over 2017 Operating earnings of $35.7 million, a 37% increase over 2017 Diluted e
Read more →SUPNSupernus to Host Second Quarter 2018 Earnings Conference Call ROCKVILLE, Md.
Supernus to Host Second Quarter 2018 Earnings Conference Call ROCKVILLE, Md., July 25, 2018 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) di
Read more →SUPNDr. Carrolee Barlow, M.D., Ph.D., Joins Supernus Board of Directors ROCKVILLE, Md.
Dr. Carrolee Barlow, M.D., Ph.D., Joins Supernus ROCKVILLE, Md., June 27, 2018 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today
Read more →SUPNSupernus to Present at the 2018 Jefferies Healthcare Conference ROCKVILLE, Md.
Supernus to Present at the 2018 Jefferies Healthcare Conference ROCKVILLE, Md., May 30, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases,
Read more →SUPNSupernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue Total revenue of $90.4 million, a 57% increase over 2017 Net product sales of $89.1 million, a 58% increase over 2017 Operating earning
Supernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue Total revenue of $90.4 million, a 57% increase over 2017 Net product sales of $89.1 million, a 58% increase over 2017 Operating earnings of $31.4 million, an 87% increase over 2017 Diluted e
Read more →SUPNSupernus to Host First Quarter 2018 Earnings Conference Call ROCKVILLE, Md.
Supernus to Host First Quarter 2018 Earnings Conference Call ROCKVILLE, Md., April 24, 2018 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) di
Read more →SUPNSupernus Announces Pricing of $350 Million Private Offering of 0.625% Convertible Senior Notes ROCKVILLE, Md.
Supernus Announces Pricing of $350 Million Private Offering of 0.625% Convertible Senior Notes ROCKVILLE, Md., March 15, 2018 (GLOBE NEWSWIRE) Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) (the Company ), a specialty pharmaceutical company focused on developing and commercializin
Read more →SUPNSupernus Pharmaceuticals Management March 2018 Presentation 2018 Supernus Pharmaceuticals, Inc. All Rights Reserved. 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be give
Baseline 70% 60% 50% 40% 30% 20% 10% 0% (n=30) (n=27) (n=30) (n=31) * Placebo (n=30) Low doseMedium High dose (n=31) (n=27) dose (n=30) Remission: RMOAS<10, P significant at p< 0.05 2 Primary Endpoint before FDA input * P<0.05 vs. placebo # Retrospective modified overt aggression
Read more →SUPNSupernus Announces Proposed Private Offering of $350 Million of Convertible Senior Notes
ROCKVILLE, Md., March 13, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) (the “Company”), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced today that, subje
Read more →SUPNSupernus to Present at the 2018 Cowen Health Care Conference ROCKVILLE, Md.
Supernus to Present at the 2018 Cowen Health Care Conference ROCKVILLE, Md., March 6, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, t
Read more →SUPNSupernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance Fourth quarter 2017 total revenue of $88.4 million, a 42% increase over 2016, and fourth quarter 2017 net product sales of
Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance Fourth quarter 2017 total revenue of $88.4 million, a 42% increase over 2016, and fourth quarter 2017 net product sales of $86.3 million, a 41% increase over 2016. Fourth quarter 2
Read more →SUPNSupernus to Host Fourth Quarter and Full Year 2017 Earnings Conference Call Rockville, Md.
Supernus to Host Fourth Quarter and Full Year 2017 Earnings Conference Call Rockville, Md., February 12, 2018 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervo
Read more →SUPNSupernus Mourns the Loss of Board Member William Nuerge
ROCKVILLE, Md., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), It is with great sadness that Supernus announces that William Nuerge, a valued member of its Board of Directors, passed away on January 10, 2018. Mr. Nuerge had a long and distinguishe
Read more →SUPNExhib it 99.1 Supernus to Present at the 2018 J.P. Morgan Healthcare Conference ROCKVILLE, Md.
Supernus to Present at the 2018 J.P. Morgan Healthcare Conference ROCKVILLE, Md., January 2, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system dise
Read more →SUPNSupernus to Present at the 2018 J.P. Morgan Healthcare Conference
ROCKVILLE, Md., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's managemen
Read more →SUPNSupernus Announces Third Quarter 2017 Financial Results Third quarter net product sales were $78.1 million, a 40% increase over 2016. Third quarter operating income was $22.3 million, a 13% increase over 2016. Initiated
Supernus Announces Third Quarter 2017 Financial Results Third quarter net product sales were $78.1 million, a 40% increase over 2016. Third quarter operating income was $22.3 million, a 13% increase over 2016. Initiated Phase III clinical trials for SPN-812. Initiated Oxtella
Read more →SUPNSupernus to Host Third Quarter 2017 Earnings Conference Call Rockville, Md.
Supernus to Host Third Quarter 2017 Earnings Conference Call Rockville, Md., October 24, 2017 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS)
Read more →SUPNSupernus Provides Update on SPN-810 Phase III Clinical Trials Rockville, Md.
Supernus Provides Update on SPN-810 Phase III Clinical Trials Rockville, Md., September 18, 2017 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CN
Read more →SUPNSupernus Defeats Second Generic Challenger to Oxtellar XR Federal Court Finds Supernus Patents Valid and Infringed by TWi ROCKVILLE, Md.
Supernus Defeats Second Generic Challenger to Oxtellar XR Federal Court Finds Supernus Patents Valid and Infringed by TWi ROCKVILLE, Md., August 15, 2017 (GLOBE NEWSWIRE) Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and
Read more →SUPNSupernus Announces Record Second Quarter 2017 Financial Results Second quarter net product sales were $73.3 million, a 46% increase over 2016. Strong acceleration in Trokendi XR prescription growth following April launch
Supernus Announces Record Second Quarter 2017 Financial Results Second quarter net product sales were $73.3 million, a 46% increase over 2016. Strong acceleration in Trokendi XR prescription growth following April launch in migraine prophylaxis in adults and adolescents. Secon
Read more →SUPNSupernus to Host Second Quarter 2017 Earnings Conference Call Rockville, Md.
Supernus to Host Second Quarter 2017 Earnings Conference Call Rockville, Md., July 19, 2017 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) di
Read more →SUPNSupernus Announces that its Partner Shire Receives FDA Approval for Mydayis for ADHD Rockville, Md.
Supernus Announces that its Partner Shire Receives FDA Approval for Mydayis for ADHD Rockville, Md., June 21, 2017 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central
Read more →SUPNSupernus to Present at Jefferies Healthcare Conference ROCKVILLE, Md.
Supernus to Present at Jefferies Healthcare Conference ROCKVILLE, Md., June 1, 2017 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today an
Read more →SUPNSupernus Announces First Quarter 2017 Financial Results Net product sales were $56.4 million, a 31% increase over 2016. Operating income was $16.8 million, a 161% increase over 2016. Diluted earnings per share were $0.19
Supernus Announces First Quarter 2017 Financial Results Net product sales were $56.4 million, a 31% increase over 2016. Operating income was $16.8 million, a 161% increase over 2016. Diluted earnings per share were $0.19, increasing by 138% over 2016. Early prescription data
Read more →SUPNSupernus to Host First Quarter 2017 Earnings Conference Call Rockville, Md.
Supernus to Host First Quarter 2017 Earnings Conference Call Rockville, Md., April 26, 2017 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) di
Read more →SUPNSupernus Receives Final FDA Approval for Trokendi XR for Migraine Prophylaxis in Adults and Adolescents Trokendi XR is the Leading Extended-Release Topiramate Product and Brand of Topiramate ROCKVILLE, Md.
Supernus Receives Final FDA Approval for Trokendi XR for Migraine Prophylaxis in Adults and Adolescents Trokendi XR is the Leading Extended-Release Topiramate Product and Brand of Topiramate ROCKVILLE, Md., April 5, 2017 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a specialt
Read more →SUPNSupernus Announces Settlement with Actavis on Trokendi XR Patent Litigation ROCKVILLE, Md.
Supernus Announces Settlement with Actavis on Trokendi XR Patent Litigation ROCKVILLE, Md., March 07, 2017 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous s
Read more →SUPNSupernus Announces Settlement with Zydus on Trokendi XR Patent Litigation ROCKVILLE, Md.
Supernus Announces Settlement with Zydus on Trokendi XR Patent Litigation ROCKVILLE, Md., March 6, 2017 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous syst
Read more →SUPNSupernus Announces Record Fourth Quarter and Full Year 2016 Financial Results Fourth quarter 2016 net product sales were $61.1 million, a 43% increase over 2015. Fourth quarter operating income was $16.3 million, a 107%
Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results Fourth quarter 2016 net product sales were $61.1 million, a 43% increase over 2015. Fourth quarter operating income was $16.3 million, a 107% increase over 2015. Fourth quarter diluted earnings per s
Read more →SUPNSupernus to Present at Cowen Health Care Conference in March
ROCKVILLE, Md., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's managemen
Read more →SUPNSupernus to Host Fourth Quarter and Full Year 2016 Earnings Conference Call Rockville, Md.
Supernus to Host Fourth Quarter and Full Year 2016 Earnings Conference Call Rockville, Md., February 13, 2017 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervo
Read more →SUPNSupernus Announces Issuance of Eighth U.S. Patent Protecting Trokendi
Supernus Announces Issuance of Eighth U.S. Patent Protecting Trokendi XR ROCKVILLE, Md., February 8, 2017 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous sy
Read more →SUPNSupernus Announces Issuance of Seventh U.S. Patent Protecting Trokendi
Supernus Announces Issuance of Seventh U.S. Patent Protecting Trokendi XR ROCKVILLE, Md., January 30, 2017 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous s
Read more →SUPNSupernus Files Form 10-Q for Third Quarter 2016 and Is Now Current with All Financial Filings Rockville, Md.
Supernus Files Form 10-Q for Third Quarter 2016 and Is Now Current with All Financial Filings Rockville, Md., January 23, 2017 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company (Company) focused on developing and commercializing products for the
Read more →SUPNSupernus to Present at the 2017 J.P. Morgan Healthcare Conference ROCKVILLE, Md.
Supernus to Present at the 2017 J.P. Morgan Healthcare Conference ROCKVILLE, Md., January 3, 2017 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system dise
Read more →SUPNSupernus Wins Appeal Case on Oxtellar XR U.S. Court of Appeals Affirms District Court s Decision on Oxtellar
Supernus Wins Appeal Case on Oxtellar XR U.S. Court of Appeals Affirms District Court s Decision on Oxtellar XR ROCKVILLE, Md., December 12, 2016 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products
Read more →SUPNSupernus Wins Appeal Case on Oxtellar XR
ROCKVILLE, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the U.S. Court of Appea
Read more →SUPNSupernus Receives Nasdaq Non-Compliance Notice
ROCKVILLE, Md., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported that, on November 14, 2
Read more →SUPNSupernus Receives Nasdaq Non-Compliance Notice Rockville, Md.
Supernus Receives Nasdaq Non-Compliance Notice Rockville, Md., November 17, 2016 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, tod
Read more →SUPNSupernus to Host a Business Update Call
ROCKVILLE, Md., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will
Read more →SUPNSupernus Announces Positive Results from Phase IIb Clinical Trial For SPN-812 in Children with ADHD
Study confirms efficacy and tolerability of SPN-812, a novel non-stimulant product, in children with ADHD Study meets primary endpoint with statistically significant reduction in ADHD symptoms Conference call and webcast to discuss results at 9:00 a.m. ET, October 11, 2016 ROC
Read more →SUPNSupernus Schedules Conference Call to Present Results of Phase IIb Clinical Trial of SPN-812 in Children with
Supernus Schedules Conference Call to Present Results of Phase IIb Clinical Trial of SPN-812 in Children with ADHD ROCKVILLE, Md., October 10, 2016 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing product
Read more →SUPNSupernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR to Include Migraine Prophylaxis in Adults ROCKVILLE, Md.
Supernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR to Include Migraine Prophylaxis in Adults ROCKVILLE, Md., August 19, 2016 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing produc
Read more →SUPNSupernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman Rockville, Md.
Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman Rockville, Md., August 12, 2016 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing pro
Read more →SUPNSupernus Announces Second Quarter 2016 Financial Results Second quarter 2016 product prescriptions totaled 123,758, a 38.9% increase over the second quarter of 2015. Net product sales for second quarter 2016 were $50.3 m
Supernus Announces Second Quarter 2016 Financial Results Second quarter 2016 product prescriptions totaled 123,758, a 38.9% increase over the second quarter of 2015. Net product sales for second quarter 2016 were $50.3 million, a 46.9% increase over the second quarter of 2015.
Read more →SUPNSupernus to Host Second Quarter 2016 Earnings Conference Call Rockville, Md.
Supernus to Host Second Quarter 2016 Earnings Conference Call Rockville, Md., July 20, 2016 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases
Read more →SUPNSupernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar
Supernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR ROCKVILLE, Md., June 22, 2016 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous syst
Read more →SUPNSupernus Provides Update on Trokendi XR Migraine sNDA and Reiterates Guidance ROCKVILLE, Md.
Supernus Provides Update on Trokendi XR Migraine sNDA and Reiterates Guidance ROCKVILLE, Md., June 16, 2016 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous sy
Read more →SUPNSupernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar
Supernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar XR ROCKVILLE, Md., June 2, 2016 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system d
Read more →SUPNSupernus to Present at June Jefferies Healthcare Conference ROCKVILLE, Md.
Supernus to Present at June Jefferies Healthcare Conference ROCKVILLE, Md., May 24, 2016 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, tod
Read more →SUPNSupernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar
Supernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar XR ROCKVILLE, Md., May 10, 2016 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous sy
Read more →SUPNSupernus Announces First Quarter 2016 Financial Results First quarter 2016 product prescriptions totaled 114,773, representing a 49.7% increase over the first quarter of 2015. Net product sales for first quarter 2016 wer
Supernus Announces First Quarter 2016 Financial Results First quarter 2016 product prescriptions totaled 114,773, representing a 49.7% increase over the first quarter of 2015. Net product sales for first quarter 2016 were $43.0 million, a 53.1% increase over the first quarter o
Read more →SUPNSupernus to Host First Quarter 2016 Earnings Conference Call Rockville, Md.
Supernus to Host First Quarter 2016 Earnings Conference Call Rockville, Md., April 19, 2016 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) di
Read more →SUPNSupernus Announces Record Fourth Quarter and Full Year 2015 Financial Results Net product sales for fourth quarter 2015 were $42.6 million, a 39.6% increase over the same quarter of 2014 and a 10.5% increase over third q
Supernus Announces Record Fourth Quarter and Full Year 2015 Financial Results Net product sales for fourth quarter 2015 were $42.6 million, a 39.6% increase over the same quarter of 2014 and a 10.5% increase over third quarter 2015. Net product sales for full year 2015 were $1
Read more →SUPNSupernus to Present at March Cowen Health Care Conference
ROCKVILLE, Md., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's managemen
Read more →SUPNSupernus to Host Fourth Quarter and Full Year 2015 Earnings Conference Call Rockville, MD
Supernus to Host Fourth Quarter and Full Year 2015 Earnings Conference Call Rockville, MD, February 18, 2016 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervou
Read more →SUPNSupernus Prevails in Oxtellar XR ANDA Litigation A Federal Court finds Supernus patents valid and Actavis infringing two of them ROCKVILLE, Md.
Supernus Prevails in Oxtellar XR ANDA Litigation A Federal Court finds Supernus patents valid and Actavis infringing two of them ROCKVILLE, Md., February 8, 2016 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commerci
Read more →SUPNSupernus Prevails in Oxtellar XR ANDA Litigation
ROCKVILLE, Md., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that following a seven-day b
Read more →SUPNSupernus Announces Distribution of Common Stock by NEA
ROCKVILLE, Md., Dec. 4, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it has received notice t
Read more →SUPNSupernus to Attend Guggenheim Securities Boston Healthcare Conference ROCKVILLE, Md.
Supernus to Attend Guggenheim Securities Boston Healthcare Conference ROCKVILLE, Md., December 2, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous sys
Read more →SUPNSupernus Announces Distribution of Common Stock by
Supernus Announces Distribution of Common Stock by NEA ROCKVILLE, Md., November 12, 2015 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, tod
Read more →SUPNSupernus to Present at Two Investor Conferences ROCKVILLE, Md.
Supernus to Present at Two Investor Conferences ROCKVILLE, Md., November 9, 2015 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today annou
Read more →SUPNSupernus to Present at Two Investor Conferences
ROCKVILLE, Md., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management
Read more →SUPNSupernus Announces Third Quarter 2015 Financial Results and Raises 2015 Guidance Third quarter product prescriptions totaled 102,831, representing a 78.0% increase over the same quarter last year and a 12.6% increase ove
Supernus Announces Third Quarter 2015 Financial Results and Raises 2015 Guidance Third quarter product prescriptions totaled 102,831, representing a 78.0% increase over the same quarter last year and a 12.6% increase over the second quarter of 2015. Net product sales for the th
Read more →SUPNSupernus Announces FDA Acceptance of sNDA to Add Migraine to Trokendi XR Label ROCKVILLE, Md.
Supernus Announces FDA Acceptance of sNDA to Add Migraine to Trokendi XR Label ROCKVILLE, Md., October 22, 2015 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) announced today that the United States Food and Drug Administration (FDA) has accepted for review the company s supplemen
Read more →SUPNSupernus to Host Third Quarter 2015 Earnings Conference Call Rockville, MD
Supernus to Host Third Quarter 2015 Earnings Conference Call Rockville, MD, October 20, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) d
Read more →SUPNSupernus Announces Settlement With Par on Trokendi XR(R) Patent Litigation
ROCKVILLE, Md., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it has entered into a settlement agreement with Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. (collectively "Par") involving the ongoing patent litigati
Read more →SUPNSupernus Announces Issuance of Fifth U.S. Patent Protecting Oxtellar XR Rockville, MD
Supernus Announces Issuance of Fifth U.S. Patent Protecting Oxtellar XR Rockville, MD, September 2, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous sy
Read more →SUPNSupernus to Attend FBR Healthcare Conference on September 9 th ROCKVILLE, Md.
Supernus to Attend FBR Healthcare Conference on September 9th ROCKVILLE, Md., August 27, 2015 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases
Read more →SUPNSupernus Announces Second Quarter 2015 Financial Results Second quarter product prescriptions totaled 91,324, representing a 99% increase over the same quarter last year and a 16% increase over the first quarter of 2015.
Supernus Announces Second Quarter 2015 Financial Results Second quarter product prescriptions totaled 91,324, representing a 99% increase over the same quarter last year and a 16% increase over the first quarter of 2015. Net product sales for the second quarter of 2015 were $34
Read more →SUPNSupernus to Host Second Quarter 2015 Earnings Conference Call Rockville, MD
Supernus to Host Second Quarter 2015 Earnings Conference Call Rockville, MD, July 20, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) dis
Read more →SUPNSupernus Corrects Earlier Statement Regarding Distribution of Common Stock by NEA
ROCKVILLE, Md., June 17, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, issues the following correction regarding th
Read more →SUPNExhibi 99.1 Supernus Announces Distribution of Common Stock by
Supernus Announces Distribution of Common Stock by NEA ROCKVILLE, Md., June 17, 2015 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today a
Read more →SUPNSupernus Announces Webcast of Investor Day on June 17, 2015
ROCKVILLE, Md., June 8, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it will webcast its Inve
Read more →SUPNSupernus Announces First Quarter 2015 Financial Results Net product sales for the first quarter of 2015 were $28.1 million, compared to $9.0 million for the same quarter last year. First quarter product prescriptions tot
Supernus Announces First Quarter 2015 Financial Results Net product sales for the first quarter of 2015 were $28.1 million, compared to $9.0 million for the same quarter last year. First quarter product prescriptions totaled 78,763, representing a 146% increase over same quarte
Read more →SUPNSupernus to Host First Quarter 2015 Earnings Conference Call Rockville, MD
Supernus to Host First Quarter 2015 Earnings Conference Call Rockville, MD, April 21, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) dis
Read more →SUPNSupernus Announces Issuance of Sixth U.S. Patent Protecting Trokendi XR Rockville, MD
Supernus Announces Issuance of Sixth U.S. Patent Protecting Trokendi XR Rockville, MD, April 02, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous syste
Read more →SUPNGeorges Gemayel, Ph.D., Joins Supernus Board of Directors Rockville, MD
Georges Gemayel, Ph.D., Joins Supernus Rockville, MD, March 23, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced
Read more →SUPNSupernus Announces Fourth Quarter and Full Year 2014 Results Cash flow positive for the fourth quarter, $5.9 million, and for the full year, $3.2 million. Net income for the fourth quarter, $4.4 million, and for the full
Supernus Announces Fourth Quarter and Full Year 2014 Results Cash flow positive for the fourth quarter, $5.9 million, and for the full year, $3.2 million. Net income for the fourth quarter, $4.4 million, and for the full year, $19.9 million. Total revenue for the fourth quart
Read more →SUPNSupernus to Present at March Cowen Conference
ROCKVILLE, Md., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's managemen
Read more →SUPNSupernus to Host Fourth Quarter and Full Year 2014 Earnings Conference Call Rockville, MD
Supernus to Host Fourth Quarter and Full Year 2014 Earnings Conference Call Rockville, MD, February 17, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervo
Read more →SUPNSupernus Sues TWi for Infringement of Oxtellar XR(R) Patents
ROCKVILLE, Md., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers TWi Pharmaceuticals, Inc. and TWi International LLC (d/b/a TWi Pharmaceuticals USA) (collectively "TWi") for infringement of four patents cove
Read more →SUPNSupernus Sues Par for Infringement of Trokendi XR Patents Rockville, MD.
Supernus Sues Par for Infringement of Trokendi XR Patents Rockville, MD., January 16, 2015 Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. (collectively Par ) for infringement
Read more →SUPNSupernus Sues Par for Infringement of Trokendi XR(R) Patents
ROCKVILLE, Md., Jan. 16, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. (collectively "Par") for infringement of four patents covering its antiepilept
Read more →SUPNSupernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R)
ROCKVILLE, Md., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on December 9, 2014 the Company received a Paragraph IV Notice Letter from TWi Pharmaceuticals, Inc. ("TWi") advising Supernus of the filing by TWi of an Abbreviate
Read more →SUPNSupernus Announces Paragraph IV ANDA Filing for Trokendi XR Rockville, MD
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR Rockville, MD, December 9, 2014 Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on December 8, 2014 the Company received a Paragraph IV Notice Letter from Par Pharmaceutical, Inc. ( Par ) advising Supe
Read more →SUPNSupernus Announces Paragraph IV ANDA Filing for Trokendi XR(R)
ROCKVILLE, Md., Dec. 9, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on December 8, 2014 the Company received a Paragraph IV Notice Letter from Par Pharmaceutical, Inc. ("Par") advising Supernus of the filing by Par of an Abbreviated
Read more →SUPNSupernus Announces Issuance of Fifth U.S. Patent Protecting Trokendi XR(R)
ROCKVILLE, Md., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a fifth pate
Read more →SUPNSupernus Sues Zydus for Infringement of Trokendi XR Patents Rockville, MD.
Supernus Sues Zydus for Infringement of Trokendi XR Patents Rockville, MD., November 21, 2014 Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited (collectively Zydus ) for infringe
Read more →SUPNSupernus Sues Zydus for Infringement of Trokendi XR(R) Patents
ROCKVILLE, Md., Nov. 21, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited (collectively "Zydus") for infringement of three patents covering its antiepile
Read more →SUPNSupernus Announces Third Quarter 2014 Results The Company raises revenue guidance from approximately $105 million to a range of $115 million to $118 million for 2014 and reaffirms cash flow break even by end of year. Tot
Supernus Announces Third Quarter 2014 Results The Company raises revenue guidance from approximately $105 million to a range of $115 million to $118 million for 2014 and reaffirms cash flow break even by end of year. Total revenue for the quarter, $52.5 million, includes $30.0
Read more →SUPNSupernus Announces Third Quarter 2014 Results
The Company raises revenue guidance from approximately $105 million to a range of $115 million to $118 million for 2014 and reaffirms cash flow break even by end of year. Total revenue for the quarter, $52.5 million, includes $30.0 million in royalty monetization revenue. Net pr
Read more →SUPNSupernus Announces Issuance of Fourth U.S. Patent Protecting Trokendi XR(R)
ROCKVILLE, Md., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a fourth pate
Read more →SUPNSupernus to Present at Two Investor Conferences Rockville, MD
Supernus to Present at Two Investor Conferences Rockville, MD, November 4, 2014 Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announce
Read more →SUPNSupernus to Host Third Quarter 2014 Earnings Conference Call Rockville, MD
Supernus to Host Third Quarter 2014 Earnings Conference Call Rockville, MD, October 29, 2014 -Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disease
Read more →SUPNSupernus Announces Paragraph IV ANDA Filing for Trokendi
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR ROCKVILLE, Md., Oct. 14, 2014 Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on October 13, 2014, the Company received a Paragraph IV Notice Letter from Zydus Pharmaceuticals (USA) Inc. ( Zydus ) advi
Read more →SUPNSupernus Sues Actavis for Infringement of Trokendi XR Patents Rockville, MD.
Supernus Sues Actavis for Infringement of Trokendi XR Patents Rockville, MD., October 2, 2014 Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that earlier today it sued generic drug makers Actavis plc, Actavis, Inc., Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Wa
Read more →SUPNSupernus Sues Actavis for Infringement of Trokendi XR(R) Patents
ROCKVILLE, Md., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that earlier today it sued generic drug makers Actavis plc, Actavis, Inc., Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Watson Laboratories, Inc., and Anda, Inc. (colle
Read more →SUPNSupernus Provides Business Update Rockville, MD
Supernus Provides Business Update Rockville, MD, September 22, 2014 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is providing the following business update in light of recent investor filings with the SEC: The Company reaffirms that it is on track to become cash flow breakev
Read more →SUPNSupernus Announces Issuance of Fourth US Patent Protecting Oxtellar XR Rockville, MD
Supernus Announces Issuance of Fourth US Patent Protecting Oxtellar XR Rockville, MD, September 4, 2014 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a specialty pharmaceutical company, today announced the issuance of a fourth patent (number 8,821,930) by the United States Pat
Read more →SUPNSupernus to Attend FBR HealthCare Conference in September
ROCKVILLE, Md., Aug. 19, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will be hosting investor meetings during the FBR Healthcare Conference. Date: Wednesday, September 3
Read more →SUPNSupernus Receives FDA Fast Track Designation for SPN-810 Rockville, MD
Supernus Receives FDA Fast Track Designation for SPN-810 Rockville, MD, August 14, 2014 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, to
Read more →SUPNSupernus Announces Second Quarter 2014 Results Second quarter combined net product revenue for Oxtellar XR and Trokendi XR was $27.6 million. Total Revenue for the first half of 2014 was a record, $38.7 million. Raising
Second Quarter 2014 Results Second quarter combined net product revenue for Oxtellar XR and Trokendi XR was $27.6 million. Total Revenue for the first half of 2014 was a record, $38.7 million. Raising guidance for annual revenues to approximately $105 million, and expecting to
Read more →SUPNSupernus Announces Second Quarter 2014 Results
Second quarter combined net product revenue for Oxtellar XR and Trokendi XR was $27.6 million. Total revenue for the first half of 2014 was a record, $38.7 million. Raising guidance for annual revenue to approximately $105 million, and expecting to be profitable for the full yea
Read more →SUPNSupernus to Host Second Quarter 2014 Earnings Conference Call Rockville, MD
Supernus to Host Second Quarter 2014 Earnings Conference Call Rockville, MD, July 29, 2014 -Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases,
Read more →SUPNSupernus to Receive $30 Million in Non-Dilutive Royalty Deal
ROCKVILLE, Md., July 8, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced the execution of a royalty acquisition agreement ("Agreement") with HealthCare Royalty Partners ("HC Royalty"). Per the Agreement, HC Royalty will make a $30 million cas
Read more →SUPNSupernus to Present at Jefferies Healthcare Conference in June
ROCKVILLE, Md., May 21, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will provide a business update and will be hosting investor meetings during the Jefferies Healthcare Co
Read more →SUPNSupernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM)
ROCKVILLE, Md., May 20, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that United Therapeutics Corporation (Nasdaq:UTHR) has paid Supernus a $2 million milestone payment under United Therapeutics' license agreement with Supernus. This payme
Read more →SUPNSupernus Receives $2 Million Milestone for United Therapeutics Launch of Orenitram Rockville, MD
Supernus Receives $2 Million Milestone for United Therapeutics Launch of Orenitram Rockville, MD, May 20, 2014 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that United Therapeutics Corporation (NASDAQ: UTHR) has paid Supernus a $2 million milestone payment under
Read more →SUPNSupernus Announces First Quarter 2014 Results First quarter product prescriptions, as reported by IMS, totaled 30,208, increasing by 9,098, or 43%, as compared to fourth quarter 2013. First quarter combined net product r
First Quarter 2014 Results First quarter product prescriptions, as reported by IMS, totaled 30,208, increasing by 9,098, or 43%, as compared to fourth quarter 2013. First quarter combined net product revenue for Oxtellar XR and Trokendi XR was $9.0 million. As of May, the sale
Read more →SUPNSupernus Announces First Quarter 2014 Results
First quarter product prescriptions, as reported by IMS, totaled 30,208, increasing by 9,098, or 43%, as compared to fourth quarter 2013. First quarter combined net product revenue for Oxtellar XR and Trokendi XR was $9.0 million. As of May, the sales force expansion is substan
Read more →SUPNSupernus to Host First Quarter 2014 Earnings Conference Call Rockville, MD
Supernus to Host First Quarter 2014 Earnings Conference Call Rockville, MD, April 29, 2014 -Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases,
Read more →SUPNSupernus Announces Fourth Quarter and Full Year 2013 Results Product prescriptions filled at the pharmacy level in the fourth quarter of 2013 increased by 12,527, or more than 100%, as compared to third quarter. Full yea
Supernus Announces Fourth Quarter and Full Year 2013 Results Product prescriptions filled at the pharmacy level in the fourth quarter of 2013 increased by 12,527, or more than 100%, as compared to third quarter. Full year net revenue for Oxtellar XR, $11.0 million, exceeded gu
Read more →SUPNSupernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call Rockville, MD
Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call Rockville, MD, February 25, 2014 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervou
Read more →SUPNSupernus Announces Publication of Phase III Study (PROSPER) Results on Oxtellar XR Rockville, MD
Supernus Announces Publication of Phase III Study (PROSPER) Results on Oxtellar XR Rockville, MD, February 3, 2014 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced the publication of the Prospective, Randomized Study of Oxcarbaz
Read more →SUPNSupernus Announces Issuance of First Use Patents Protecting SPN-812 as a Novel Non-Stimulant ADHD Product
ROCKVILLE, Md., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of a European patent (number 2341912) and Canadian patent (number 2,735,934) for SPN-812, its novel non-stimulant produ
Read more →SUPNSupernus Announces Issuance of First Use Patents Protecting SPN-812 as a Novel Non-Stimulant ADHD Product Rockville, MD
Supernus Announces Issuance of First Use Patents Protecting SPN-812 as a Novel Non-Stimulant ADHD Product Rockville, MD, January 27, 2014 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced the issuance of a European patent (number
Read more →SUPNSupernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R)
ROCKVILLE, Md., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of a third patent (number 8,617,600) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR , its
Read more →SUPNSupernus Announces Resignation of Board Member
ROCKVILLE, Md., Dec. 24, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, announced today that Michael Bigham, a General Partner at Abingworth has resigned from the company's board of directors, effective December 23, 2013
Read more →SUPNSupernus Announces FDA Approval of Its Partner's Product, Orenitram(TM)
ROCKVILLE, Md., Dec. 23, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, announced today that the FDA approved Orenitram (treprostinil), Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH)
Read more →SUPNSupernus Posts Exciting Clinical Data Regarding Trokendi XR(TM) and Oxtellar XR(TM) on the Company Website
ROCKVILLE, Md., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the clinical data that was released at the American Epilepsy Society (AES) Meeting in December in Washington DC is now availabl
Read more →SUPNSupernus to Present at Piper Jaffray Healthcare Conference in December
ROCKVILLE, Md., Nov. 21, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will present an overview of the Company at the Piper Jaffray Healthcare Investor Conference. Presenta
Read more →SUPNSupernus Pharmaceuticals Reports Third Quarter 2013 Financial Results
ROCKVILLE, Md., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2013 and provided an update on key accomplishments to date. "As
Read more →SUPNSupernus Announces Third Quarter 2013 Earnings Conference Call and Webcast
ROCKVILLE, Md., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced that the Company expects to report financial results for the quarter ended September 30, 2013 after the market closes on Tuesday November 12, 2013. Supernus will host a
Read more →SUPNSupernus Announces Release of Exciting New Clinical Data on Trokendi XR(TM)
ROCKVILLE, Md., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that new clinical data will be released at the American Epilepsy Society (AES) Meeting this coming December in Washington DC. The fi
Read more →SUPNSupernus Launches Trokendi XR(TM) in the United States
ROCKVILLE, Md., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that Trokendi XR is now available to patients in the United States. Trokendi XR is a novel once-daily extended release formulation o
Read more →SUPNSupernus to Present at Two Investor Conferences in September
ROCKVILLE, Md., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will present an overview of the Company at the following investor conferences in September 2013: Rodm
Read more →SUPNSupernus Announces Final FDA Approval and Upcoming Launch of Trokendi XR(TM)
ROCKVILLE, Md., Aug. 19, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, received final approval from the Food & Drug Administration (the "FDA") for Trokendi XR, a novel once-daily extended release formulation of topirama
Read more →SUPNSupernus Pharmaceuticals Reports Second Quarter 2013 Financial Results
ROCKVILLE, Md., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported financial results for the three and six months ended June 30, 2013, and provided an update on key accomplishments to date. "Oxtellar
Read more →SUPNSupernus Sues Watson for Infringement of Oxtellar XR(TM) Patents
ROCKVILLE, Md., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that earlier today it sued generic drug makers Actavis Inc., Watson Laboratories, Inc. - Florida, Actavis Pharma, Inc., Watson Laboratories, Inc., and Anda, Inc. (collectively
Read more →SUPNSupernus Announces Second Quarter 2013 Earnings Conference Call and Webcast
ROCKVILLE, Md., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced that the Company expects to report financial results for the quarter ended June 30, 2013 after the market closes on Tuesday August 13, 2013. Supernus will host a confere
Read more →SUPNSupernus Announces Paragraph IV ANDA Filing for Oxtellar XR(TM)
ROCKVILLE, Md., June 27, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on June 26, 2013 the Company received a Paragraph IV Notice Letter from Watson Laboratories, Inc. ("Watson") advising Supernus of the filing by Watson of an Abbrevi
Read more →SUPNSupernus Receives Tentative Approval for Trokendi XR(TM)
ROCKVILLE, Md., June 10, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, received a tentative approval letter from the Food & Drug Administration (the "FDA") for Trokendi XR , a novel once-daily extended release formulati
Read more →SUPNSupernus Pharmaceuticals Reports First Quarter 2013 Financial Results
ROCKVILLE, Md., May 13, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported financial results for the three months ended March 31, 2013, and provided an update on key accomplishments to date. "Oxtellar XRTM co
Read more →SUPNSupernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019
ROCKVILLE, Md., May 6, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) ("Supernus") announced today the closing of its previously announced private offering of 7.50% Convertible Senior Secured Notes due 2019 (the "Convertible Notes"). Supernus issued $90 mil
Read more →SUPNSupernus Announces First Quarter 2013 Earnings Conference Call and Webcast
ROCKVILLE, Md., May 6, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced that the Company expects to report financial results for the quarter ended March 31, 2013 after the market closes on Monday May 13, 2013. Supernus will host a conference
Read more →SUPNSupernus Prices Offering of $75 Million of 7.50% Convertible Senior Secured Notes Due 2019
ROCKVILLE, Md, April 26, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) ("Supernus") today announced the pricing of its offering of $75.0 million aggregate principal amount of Convertible Senior Secured Notes due 2019 (the "Convertible Notes") in a private
Read more →SUPNSupernus Announces Proposed Offering of $75 Million of Convertible Senior Secured Notes
ROCKVILLE, Md., April 24, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) ("Supernus") today announced that it intends to offer, subject to market and other considerations, $75.0 million aggregate principal amount of Convertible Senior Notes due 2019 (the "C
Read more →SUPNSupernus Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Financial Results
ROCKVILLE, Md., March 14, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2012, and provided an update on key accomplishments to date. S
Read more →SUPNSupernus Announces Year-End and Fourth Quarter 2012 Earnings Conference Call and Webcast
ROCKVILLE, Md., March 7, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced that the Company expects to report the quarter and year ending December 31, 2012 financial results after the market closes on Thursday, March 14, 2013. Supernus will ho
Read more →SUPNSupernus Launches Oxtellar XR(TM) in the United States
ROCKVILLE, Md., Feb. 1, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that Oxtellar XR tablets are now available for sale in the US. Oxtellar XR is a novel once-daily extended release antiepileptic drug
Read more →SUPNSupernus Appoints Victor Vaughn as Senior Vice President of Sales
ROCKVILLE, Md., Jan. 14, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the appointment of Victor Vaughn to the position of Senior Vice President of Sales. Mr. Vaughn will be responsible for leading all o
Read more →SUPNSupernus Announces Pricing of Public Offering
ROCKVILLE, Md., Nov. 29, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company announced the pricing of the underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. Supern
Read more →SUPNSupernus Announces Positive Phase IIb Results on SPN-810 and Decision to Advance to Late Stage Development
ROCKVILLE, Md., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, received positive topline results from its Phase IIb study on SPN-810 for the treatment of impulsive aggression in ADHD patients. The study is a mu
Read more →SUPNSupernus Receives Three Years of Market Exclusivity for Oxtellar XR(TM)
ROCKVILLE, Md., Nov. 19, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, announced today that it has received confirmation from the Food and Drug Administration (the "FDA") that Oxtellar XR has been granted three years of
Read more →SUPNSupernus Pharmaceuticals Reports Third Quarter 2012 Financial Results
ROCKVILLE, Md., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, reported in the November 2, 2012 filing of the Form 10-Q consolidated financial results for the three and nine months ended September 30, 2012, and p
Read more →SUPNSupernus Announces Issuance of Two Patents Covering Trokendi XR(TM)
ROCKVILLE, Md., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of two patents (8,298,576 and 8,298,580) by the US Patent and Trademark Office (USPTO) covering Trokendi XR , its novel
Read more →SUPNSupernus Receives FDA Approval for Oxtellar XR(TM) in Epilepsy
ROCKVILLE, Md., Oct. 22, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, received approval from the Food & Drug Administration (the "FDA") for Oxtellar XR , a novel once-daily extended release formulation of oxcarbazepine
Read more →SUPNSupernus to Present at Two Investor Conferences in September 2012
ROCKVILLE, Md., Aug. 29, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the company's management will present an overview of the company at the following investor conferences in September: Stifel Ni
Read more →SUPNSupernus Pharmaceuticals Reports Second Quarter 2012 Financial Results
ROCKVILLE, Md., Aug. 10, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported consolidated financial results for the three and six months ending June 30, 2012, and provided an update on key accomplishments to da
Read more →SUPNSupernus Appoints Dr. Stefan Schwabe, MD, PhD as Exec. VP R&D and Chief Medical Officer
ROCKVILLE, Md., July 20, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that Dr. Stefan Schwabe MD, PhD has joined the Company as Executive Vice President of Research and Development and Chief Medical Officer. In this role, Dr. Schwabe will
Read more →SUPNSupernus Provides Update on the Launch of Its Two Epilepsy Products Trokendi XR(TM) and SPN-804
ROCKVILLE, Md., July 13, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceuticals company, announced on June 26 that it received a tentative approval letter from the Food & Drug Administration (the "FDA") for Trokendi XR , a once-daily ex
Read more →SUPNSupernus Receives Tentative Approval of Trokendi XR(TM) From FDA
ROCKVILLE, Md., June 26, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceuticals company, received a tentative approval letter from the Food & Drug Administration (the "FDA") for Trokendi XR , a once-daily extended release formulation of
Read more →SUPNSupernus Pharmaceuticals Reports First Quarter 2012 Financial Results
ROCKVILLE, Md., June 7, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported consolidated financial results for the first quarter of 2012, and provided an update on key accomplishments to date and expected miles
Read more →SUPNSupernus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
ROCKVILLE, Md., May 4, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) (the "Company"), today announced the closing of its initial public offering of 10,000,000 of its common stock at a price of $5.00 per share. The Company's shares are listed on The NASDAQ
Read more →SUPNSupernus Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
ROCKVILLE, Md., April 30, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) (the "Company") today announced the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The Company's shares are expected to begin trading o
Read more →Competitive Position
How SUPN ranks across every disease it competes inCompetitive Position is a premium feature
See how SUPN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial